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The advent of new sequencing technology has resulted in the accumulation of a large 
amount of information on human DNA variation. In order to make sense of these data 
in the context of biology and medicine, new methods are needed both for analysis and 
for integration with other resources. In this work: 1) I studied the distribution pattern 
of human DNA variants across populations using data from the 1000 genomes project 
and investigated several evolutionary biology questions from the perspective of 
population genomics. I found population level support for trends previously observed 
between species, including selection against deleterious variants, and lower frequency 
of variants in highly expressed genes and highly connected genes. I was also able to 
show that the correlation between synonymous and non-synonymous variant levels is 
  
a consequence of both mutation prevalence variation across the genome and shared 
selection pressure. 2) I performed a systematic evaluation of the effectiveness of 
GWAS (Genome Wide Association Studies) for finding potential drug targets and 
discovered the method is very ineffective for this purpose. I proposed two reasons to 
explain this finding, selection against variants in drug targets and the relatively short 
length of drug target genes. I discovered that GWAS genes and drug targets are 
closely associated in the biological network, and on that basis, developed a machine 
learning algorithm to leverage the GWAS results for the identification of potential 
drug targets, making use of biological network information. As a result, I identified 
some potential drug repurposing opportunities.  3) I developed a method to increase 
the number of protein structure models available for interpreting the impact of  
human non-synonymous variants, important for not only the understanding the 
mechanisms of genetic disease but also in the study of human protein evolution. The 
method enables the impact of approximately 40% more missense variants to be 
reliably modeled.  In summary, these three projects demonstrate that value of 
computational methods in addressing a wide range of problems in protein structure, 
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Chapter 1: Introduction 
In recent years, Next Generation Sequencing (Bentley, Balasubramanian et al. 2008; 
Eid, Fehr et al. 2009; Rothberg, Hinz et al. 2011) has greatly accelerated the 
generation of biological sequencing data. The explosive amount of sequencing data, 
combined with various other “Omics” data, allows protein biologists to study 
biological and biomedical problems at a new level, and opens new opportunities for 
both basic research and translational medicine. In this thesis, we look at three closely 
related topics in computational biology studies of proteins that are deeply influenced 
by this new technology: Protein evolution, GWAS studies, and protein structure 
modeling. 
 
1.1: Human single nucleotide variants and evolutionary biology 
Since the invention of protein sequencing methods in the late 1940s (Edman 1949), 
multi-species sequence analyses have been applied to study many questions in 
evolutionary biology. These methods have led to many significant insights and 
results, for example the construction of a tree of life (Sugden, Jasny et al. 2003), the 
discovery of  lateral gene transfer  (Koonin, Makarova et al. 2001), and identification 
of possible mechanisms for the generation of new proteins (Hughes 1994; Pegueroles, 
Laurie et al. 2013).  On the other hand, population genetics has used theoretical 
approaches (Crow and Kimura 1970; Ewens 1990)  and computer simulations 




explain various observations, such as the increase in gene number (Lynch and Conery 
2003) and expansion in the size and number of intragenic spacers (Lynch and Conery 
2003) , as well as dramatic proliferation of mobile genetic elements in multicellular 
eukaryotic organisms (Lynch and Conery 2003; Lynch 2007), based on the genetic 
drift and selection models (Hartl and Clark 1997). 
 
There is a long history of using experimental populations to demonstrate simple 
population genetics rules. For example, Buri (Buri 1956) tested the process of allele 
fixation and elimination under genetic drift through the construction and maintenance 
of experimental populations of Drosophila for 19 generations. That work found the 
fixation and elimination of eye color mutations, which are considered neutral, 
followed the predictions of the genetic drift theory. With the development of 
sequencing technology, it became possible to study population genetics using high 
quality sequence data on a large scale.  For example, a long term E.coli evolution 
experiment (Blount, Borland et al. 2008), started in 1988, has illuminated the genetic 
basis and evolutionary process underlying the Cit+ trait (ability to grow on citrate 
under oxygen-rich conditions) in unprecedented detail (Blount, Barrick et al. 2012). 
Such direct observation of the adaptation process through sequencing of multiple 
generations of E.coli populations provides new insight into how biological functions 
emerge.  
 
The recent breakthrough in next generation sequencing technology (Bentley, 




large scale genotyping of human genomes possible. The 1000 genomes project 
(Durbin, Altshuler et al. 2010) provides us with more than 1000 complete genomes 
from 14 populations of different ethnic backgrounds. This resource captures up to 
98% of accessible Human single nucleotide variations (SNVs) at a frequency of 1% 
or higher and so allows us to study a series of population genomics problems related 
to protein sequence evolution.  
 
In the first project of this thesis, we address several questions about protein sequence 
evolution using the SNV data from the 1000 genome project: (1) How does the fitness 
impact of non-synonymous SNVs affect their population frequency distribution? (2) 
What is the relationship between the distribution pattern of non-synonymous, 
synonymous, and intron SNVs for the same protein?   (3) How do the factors that are 
most strongly coupled with protein evolutionary rate such as mRNA expression level 
(Drummond and Wilke 2008), influence the distribution of human variants?  
 
Our study shows that population allele frequency of a SNV correlates negatively with 
its impact, as expected from the theory of purifying selection (Hughes, Packer et al. 
2003; Bustamante, Fledel-Alon et al. 2005). Synonymous SNV density and non-
synonymous SNV density correlate with each other, and they both correlate strongly 
with intron SNV density. This is compatible with the correlation between dN (protein 
non-synonymous evolutionary rate) and dS (protein synonymous evolutionary rate) 
discovered in both bacteria and mammals (Li, Wu et al. 1985; Sharp and Li 1987) 




synonymous SNV density but not synonymous SNV density, compatible with the 
well-known correlation between mRNA expression level and protein evolutionary 
rate. In summary, our studies demonstrate that high throughput sequencing data can 
supplement multi-species protein sequence comparison studies to help us understand 
the protein sequence evolution from a different perspective. 
 
1.2: GWAS and drug targets 
In addition to evolutionary biology, another field that benefits greatly from the new 
sequencing technology is that of GWA studies. GWAS (Genome Wide Association 
Study) is a method to examine many genetic variants and to determine whether the 
presence or absence of any variants is associated with a trait, usually a complex 
disease. The studies usually compare genetic markers or DNA sequences collected 
from two groups: people with the trait (case) and people without the trait (control) 
and detect those genetic markers, usually SNPs (Single Nucleotide Polymorphisms), 
that have significantly different frequency in the case and control groups. There have 
been thousands of GWA studies for different complex diseases in different 
populations. The GWAS catalog (http://www.genome.gov/gwastudies/) is a central 
depositary for results of GWAS studies.  
 
In a typical GWA study, DNA samples extracted from a few hundreds to thousands 
of case and control people are genotyped using DNA chip technology, which is a fast 




Nucleotide Polymorphism (SNPs) for a DNA sample (DiStefano and Taverna 2011). 
The SNPs on a chip (tag SNPs) are a representative subset that are correlated with 
other SNPs through Linkage Disequilibrium (Jorde 1995) (LD), thus almost every 
common SNP has a closely correlated tag SNP (Ohashi and Tokunaga 2001).  
Detection of SNP-phenotype associations requires a large sample size. Meta-studies, 
the practice of using data from multiple GWA Studies of the same disease together, 
can increase the effective population size, thus increasing the statistical power to 
detect weak associations (Zeggini and Ioannidis 2009; Thompson, Attia et al. 2011). 
Meta-studies have been used for a number of complex diseases and have identified 
new loci not found by the regular GWAS method (Franke, McGovern et al. 2010; 
Stahl, Raychaudhuri et al. 2010). 
 
The second project – GWAS identified genes and Drug Targets, is motivated by the 
puzzling observation that GWA studies do not identify the most important genes for 
blood pressure regulation. There is a long history of identification of genes affecting 
blood pressure using non-genomic methods, and 30 genes discovered in this way 
have provided successful targets for treating hypertension (Johnson, Newton-Cheh et 
al. 2011). A study has found that among 14 GWAS blood pressure associated genes, 
only two are in a previous list of 160 traditional candidates (Ehret 2010) and none are 
established drug targets. This led us to examine whether this phenomenon is common 
for other diseases. We compared a set of 1621 reported mechanism genes in the 
GWAS catalog (www.genome.gov/gwastudies (Hindorff, Sethupathy et al. 2009), 




from Drugbank (Knox, Law et al. 2011), January 2012) for the same diseases. If drug 
targets were found by GWAS, there should be a large overlap of these two sets. In 
fact, only 20 of the 856 drug target genes are discovered in GWAS studies of the 
same disease.  We showed that a possible explanation for this is that the drug targets 
are more tightly coupled with the disease phenotype, thus have fewer variants than 
are detectable by GWAS. We then look at the relationship between GWAS reported 
genes and corresponding drug targets in a protein interaction network (Wu, Feng et 
al. 2010). The network is a protein functional interaction network generated by 
extending curated biological pathways with non-curated sources of information, 
including protein-protein interactions, gene co-expression, protein domain interaction, 
Gene Ontology (GO) annotations and text-mined protein interactions, and covers 
about 50% of human genes. We found GWAS genes and drug targets for a specific 
disease are closely related to each other in the network. We exploit that finding to 
develop a protein network based method for predicting potential drug targets from 
GWAS identified genes, and as a result were able to propose several possibilities for 
drug repurposing. 
 
1.3: Protein structure modeling 
To fully take advantage of the newly generated human SNV data and GWAS results, 
it’s important to measure the biological impact of SNVs. For non-synonymous SNVs, 
the best way to look at impact is to put them in the context of protein three 




limited by the low experimental coverage of human proteins: for example, currently, 
only around 8% of the sites of common missense single nucleotide variants lie within 
an experimentally determined structure of the corresponding protein. In order to 
analyze a larger proportion of non-synonymous SNVs, it is necessary to extend the 
experimental coverage using models of structure.    
 
Protein structure modeling is the practice of predicting protein three- dimensional 
structure based on protein sequence. Generally speaking, there are two kinds of 
structure modeling methods: de novo methods (Lee, Liwo et al. 1999; Rohl and Baker 
2002; Chikenji, Fujitsuka et al. 2003; Bradley, Misura et al. 2005; Floudas, Fung et 
al. 2006; Hung, Ngan et al. 2007) and homology modeling (Sali and Blundell 1994; 
Cardozo, Totrov et al. 1995; Bower, Cohen et al. 1997; Bordoli, Kiefer et al. 2008; 
Moult 2008) . De novo methods predict the protein structure from physics and 
chemistry principles without any template. On the other hand homology modeling 
predicts the structure of a target protein based on the known structure of a closely 
related template protein. The quality of homology modeling depends on the sequence 
identity between the template and the target. Models of different qualities have 
different applications (Moult 2008). High quality models are useful in fields that 
require high accuracy such as drug design, while models of low quality are often 
useful in gene function annotation, for example. For the purpose of predicting the 
impact of human missense single-nucleotide variants (SNVs), intermediate quality 
models are required, and it’s usually possible to make a reasonable prediction using 




in SNV impact prediction using lower sequence identity models is mis-alignment of 
the target and template sequences, rather than long term structural divergence. In the 
third project, we therefore designed a method to filter out models built with bad 
alignments and use only those with reliable ones. We developed a dynamic 
programming based algorithm to evaluate the quality of pairwise protein sequence 
alignments and demonstrated that we can model more non-synonymous variants and 
analyze their impact with reasonable accuracy. 
 
1.4: Overview 
The dissertation is organized as follows. Chapter 2 first discusses the relationship 
between evolutionary biology and population genomics, then goes through a series of 
topics on the distribution pattern of human variants, discussing their implications in 
protein evolution. Chapter 3 discusses the finding that GWAS usually does not 
identify genes most tightly coupled to the disease mechanism, and proposes an 
explanation for it. Then we describe a protein network based method to overcome this 
issue. Chapter 4 introduces a new algorithm to evaluate the accuracy of pairwise 
protein sequence alignment, and then demonstrates its application in human missense 
SNV impact modeling.  Chapter 5 summarized the conclusion of the three projects 







Chapter 2: Distribution of human single nucleotide variants and 
implications for protein sequence evolution 
2.1: Introduction  
Protein sequence evolution is a central topic in biology. Knowledge of this process 
can help us understand the process of speciation (Webster, Payne et al. 2003), 
facilitate the identification of functionally important sites in proteins (Reetz, Wang et 
al. 2006),  find protein interaction partners (Ramani and Marcotte 2003), predict 
protein structure (Hopf, Colwell et al. 2012), and predict the impact of non-
synonymous variants in human disease (Ng and Henikoff 2003; Yue, Melamud et al. 
2006). Inter-species sequence analyses have revealed many features of protein 
sequence evolution. For example, positive correlations between dN, non-synonymous 
mutation rate, and dS, synonymous mutation rate, have been discovered in both 
mammals (Wolfe and Sharp 1993) and bacteria (Sharp and Li 1987). Combined 
analysis of inter-species protein sequence alignment and large-scale biological 
experimental data have identified several factors that significantly influence the rate 
of protein sequence evolution, such as mRNA expression level (Drummond and 
Wilke 2008) and the number of protein-protein interactions (Pal, Papp et al. 2006). 
With the development of next generation sequencing technology (Bentley, 
Balasubramanian et al. 2008; Eid, Fehr et al. 2009; Rothberg, Hinz et al. 2011), we 




allow us to revisit these observations from the perspective of intra-species sequence 
analysis.  
 
There is a long history of population genetics studies of the evolution process through 
intra-species sequence comparison. In particular, a number of statistical measures 
have been developed for assessing deviations from neutrality. For example, Tajima’s 
D is a measure based on the difference between the observed number of pairwise 
segregating sites and the number of pairwise segregating sites expected from the total 
polymorphic sites for a group of sequences based on a neutral model (Tajima 1989). 
Other widely used statistics include Fu’s F (Fu 1995), Fay Wu’s H (Fay and Wu 
2000), and Zeng’s E (Zeng, Fu et al. 2006) are all based on the difference between 
some observed quantity and the expectation for that quantity from the assumption of 
neutrality. These measures have been used in studies for model organisms (Bachtrog 
2004) , agriculture plants (Wright, Bi et al. 2005), pathogens (Shriner, Shankarappa et 
al. 2004) and human populations. Studies range from small scale (a couple of genes) 
(Polley and Conway 2001) to a moderately large scale (hundreds of genes) (Stephens, 
Schneider et al. 2001; Akey, Eberle et al. 2004), with the general goal of finding  
genes or more broadly speaking regions of DNA that deviate from neutrality. The 
results have provided extensive information on regions undergoing both negative and 
positive selection, as well some artificial selection (Wright, Bi et al. 2005) for some 
plants.  
 




evolution is the Mcdonald Kreitman test (McDonald and Kreitman 1991). This test is 
designed to detect positive selection based on the contrast between the inter-species 
divergence pattern and the intra-species polymorphic pattern, comparing the ratio 
between the number of polymorphic and fixed sites for synonymous mutations with 
that for non-synonymous mutations. The test has been applied to many model 
organisms (Nachman, Boyer et al. 1994; Smith and Eyre-Walker 2002) and has 
provided information on the extent of adaptive evolution between specie, showing 
this to vary widely over mammals,  Drosophila, plants and bacteria (Eyre-Walker 
2006).  
 
 A suitable measure for specifically studying variation within a population and its 
relationship to other factors is single nucleotide variant (SNV) density. For example, 
early studies (Zhao, Fu et al. 2003) calculated the SNP (Single Nucleotide 
Polymorphism) density for different categories of human SNPs, (Chen and Rajewsky 
2006) used SNP density to measure selection on miRNA binding sites. (Gerstein, 
Kundaje et al. 2012) used non-synonymous SNV density together with dN/dS values 
to measure the selection pressure for  different genes in the analysis of a human 
regulatory network constructed from ENCODE project data (Ecker, Bickmore et al. 
2012) . At the population level, non-synonymous SNV density, Nd, reflects the 
tolerance of a gene to non-synonymous mutations, and so can be considered a 
population level measure of dN. Similarly the synonymous SNV density, Sd, can be 
considered a population level measure of dS. There is an important difference 




measure the rate of substitutions along divergent lineages—i.e., the rate at which 
mutations arise and subsequently fix; whereas the two densities focus on the behavior 
of segregating mutations in the process of elimination and fixation. Nevertheless, they 
are all directly related to protein sequence evolution and give us measures of the 
variability of protein sequence at two different levels. 
 
One of the disadvantages of this type of analysis is that the density treats every 
variant equally, regardless of population frequency. The population frequency of a 
variant in part reflects the selection pressure acting on it, so that common variants are 
more likely to be neutral than rare ones (Hughes, Packer et al. 2003; Bustamante, 
Fledel-Alon et al. 2005) . The other disadvantage is that the approach treats every 
variant independently, thus neglecting the fine structure of linkage between variants. 
Previous studies have shown that there is significant hitchhiking of variants in coding 
and regulatory sites in human (Cai, Macpherson et al. 2009), so the density is to some 
extent distorted by such effects. Both factors may reduce but not invalidate the signals 
caused by the functional factors that protein evolutionary biologists are interested in. 
The advantage of the density measure is its relevance to the multi-species protein 
sequence analysis measures such as dN and dS.  That relationship allows us to 
translate certain protein sequence evolution problems previously studied at the multi-
species level into the language of population genomics, and thus study these problems 
from that perspective. 
  




characterize the geographic and functional spectrum of human genetic variation, has 
provided us with more than 1000 complete genomes from 14 populations of different 
ethnic backgrounds. It allows us to study a lot of human population genomics 
problems which are impossible before.  In this project, we first look at the 
relationship between the impact of non-synonymous single nucleotide variants 
(SNVs) and population allele frequencies, and show a significant negative correlation 
between these quantities, as is expected from the theory of purifying selection 
(Hughes, Packer et al. 2003; Bustamante, Fledel-Alon et al. 2005). We then revisited 
the problem of correlation between dN and dS using these SNV densities and found 
significant correlation between non-synonymous variant density and synonymous 
variant density, consistent with the previously observed correlation between dN and 
dS (Sharp and Li 1987; Wolfe and Sharp 1993) .  The correlation suggests non-
synonymous and synonymous sites may be under the influence of some common 
factors. An alternative explanation for the correlation between dN and dS is that it 
reflects the fluctuation of local mutation prevalence (Ohta and Ina 1995), so that dN 
and dS are both high in high mutation prevalence regions of the genome and both low 
in low mutation prevalence regions. Studies have found that the variability of 
mutation prevalence across the genome can be ascribed to unexpected factors such as 
distance to nearby insertions and deletions (Tian, Wang et al. 2008). Later studies of 
the same subject argued that the increased mutation prevalence near indels is caused 
by nearby repeated sequences, which promotes an increased probability of replication 
fork arrest, causing the persistent recruitment of error-prone DNA polymerases 




mutation prevalence across mammalian genomes is adaptive or not (Hodgkinson and 
Eyre-Walker 2011). In C.elegans, it has been found that the rate of spontaneous 
single-base mutation is uniform on a chromosome scale (Denver, Dolan et al. 2009) 
and the observed prevalence of variations is dominated by background selection: 
There is a reduction in neutral variation due to linkage between neutral variants and 
deleterious mutations undergoing elimination from the population (Hudson and 
Kaplan 1995), a process highly dependent on the local recombination rate (Rockman, 
Skrovanek et al. 2010) .  In this study, we measure the local mutation prevalence 
through the variant density of introns.  
 
Introns comprise 37% of the human genome (Fedorova and Fedorov 2005). SNVs in 
introns do not change coding sequence or codon usage, and are thus unlikely to have 
any impact on protein structure and function, or on translation efficiency. Introns may 
be involved in regulation of gene expression (Ratajewski, de Boussac et al. 2012) and 
mutations in introns may cause splicing errors (Kulseth, Berge et al. 2010). The 
functional roles of introns and their importance to the fitness of individuals are under 
debate (Parenteau, Durand et al. 2008; Melamud and Moult 2009). Whatever 
functional roles may eventually become clear, it is already evident that most of the 
bases in these regions are not involved in function, and so intron variation provides a 
useful tool for measuring the local mutation prevalence of DNA. For example, (Metz, 
Robles-Sikisaka et al. 1998) used the substitution rate in introns as a reference to 
detect positive selection in abalone sperm fertilization genes. (Parsch, Novozhilov et 




genes. We calculated the SNV density for introns using the 1000 genome data and 
found significant correlation between this quantity with both the density of non-
synonymous SNVs and the density of synonymous SNVs, consistent with variation in 
mutation prevalence across the genome driving the correlation of non-synonymous 
and synonymous SNV densities. This observation suggests the correlation between 
non-synonymous SNV density and synonymous SNV density could be the byproduct 
of their common correlation with the SNV density of introns, which is a measure of 
local mutation prevalence. We used partial correlation analysis to look at the 
correlation between synonymous SNV density and non-synonymous SNV density 
with the effect of intron SNV density removed. Partial correlation (Johnson and 
Wichern 2002; Baba, Shibata et al. 2004) is a statistical procedure to remove the 
effect of a third random variable when calculating the correlation between two 
random variables. The analysis showed that the correlation between density of 
synonymous SNV and density of non-synonymous SNV can’t be fully explained by 
their common correlation with intron SNV density. 
 
 Studies have shown that an unexpected factor, mRNA expression level, is the most 
significant determinant of evolutionary clock rate. significant negative correlations 
between protein sequence divergence rate and mRNA expression level have been 
found in bacteria (Rocha and Danchin 2004), yeast (Drummond, Raval et al. 2006), 
worm (Krylov, Wolf et al. 2003), plants (Wright, Yau et al. 2004), fruit flies (Lemos, 
Bettencourt et al. 2005) and humans (Subramanian and Kumar 2004). Drummond and 




2008) in terms of selection against misfolded proteins: Mutations in proteins lead to 
protein misfolding, leaving exposed hydrophobic residues.  These residues will bind 
to hydrophobic sites on other proteins, leading to protein aggregation, which has 
serious consequences for the fitness of the cell (Bucciantini, Giannoni et al. 2002). 
Drummond and Wilke argued that this effect increases with expression level leading 
to the observed negative correlation between mRNA expression level and protein 
sequence evolutionary rate. These analyses are all based on inter-species protein 
sequence comparisons to determine rates. Here we look at the problem from 
population genomics perspective by examining the relationship between non-
synonymous SNV density and mRNA expression level. We observed that non-
synonymous SNV density negatively correlates with mRNA expression level. We did 
not observe significant correlation between synonymous SNV density and mRNA 
expression level, inconsistent with the inter-species results. We also looked at the 
correlation between non-synonymous variant density and the number of protein-
protein interactions. A previous study showed that the number of protein-protein 
interactions is  also a determinant of protein evolutionary rate, though not as strongly 
as mRNA expression level (Pal, Papp et al. 2006). Some studies suggest that only the 
most prolific interactors tend to evolve slowly (Jordan, Wolf et al. 2003), but other 
studies suggests that the weaker overall correlation is the result of incomplete 
interaction data, and once  a complete interactome is included, the correlation is 
significant (Fraser, Wall et al. 2003) . At the population level, we found significant 
correlation between non-synonymous SNV density and the number of protein-protein 




the influence of number of protein-protein interactions on the non-synonymous SNV 
density is independent of the influence of mRNA expression level. 
 
Finally, we look at genes that deviate from these general trends and examined the 
functions of these “outlier” genes, discovering interesting patterns for them. 
 
2.2: Results 
Deleterious variants occur at lower frequencies than neutral variants. 
Deleterious SNVs are under purifying selection, so it’s expected that their frequencies 
would be lower than those of neutral SNVs. We use the SNPs3D profile method 
(Yue, Melamud et al. 2006) to calculate the expected impact on in vivo protein 
function of the non-synonymous SNVs in the 1000 genomes data. The SNPs3D 
profile method uses a support vector machine (SVM) which returns a score related to 
the probability that a SNV is deleterious. The more negative the score, the more 
probable that SNV is deleterious. We found the fraction of predicted deleterious 
SNVs decreases with increasing allele frequency. This is consistent with the 
population genetics model: Neutral variants are more likely to reach high frequency 
and even fixation in the population while deleterious variants are more likely to be 
eliminated, though their chance of fixation is not zero (Hartl and Clark 1997). Similar 










Figure 2.1 Number of predicted deleterious and neutral single ns-SNVs in the 1000 
genomes data as a function of allele frequency. Most alleles occur at a frequency of 
less than 0.5%. The fraction of SNVs that are predicted deleterious is much higher 
(approaching 50%) in the low frequency SNVs. Above 5% frequency the fraction 
predicted deleterious is 22.5%. 
 
Correlation between non-synonymous and synonymous variant density 
We observed a substantial positive correlation between synonymous and non-




observations of a correlation between dN and dS. As noted earlier, there are two 
suggested explanations for these correlations – selection for codon use and variation 
in local mutation prevalence across the genome. Rates of sequence change in introns 
can in principle provide a useful means of distinguishing between these possibilities. 
If the cause is variation in local mutation rate there will be a correlation between the 
intron rate of change and coding related rates. But due to varying intron structures 
between species, the calculation of substitution rate in these regions is not possible 
except for closely related species such as Human and chimpanzee (Gazave, Marqués-
Bonet et al. 2007). An advantage of population data is that we can calculate SNV 
density, Id, in introns, providing a good measure of local mutation prevalence. We 
find a correlation between intron SNV density and both non-synonymous SNV 
density (Correlation: 0.37, p<2.2e-16) and synonymous SNV density (Correlation: 
0.39, p<2.2e-16) (Figure 2.2C, 2.2D).  Thus there are correlations between all pairs of 
densities: Nd with Sd, Nd with Id, and Sd with Id. To test whether the correlation 
between synonymous SNV density and non-synonymous SNV density is the 
consequence of regional mutation prevalence variation, we calculated partial 
correlation (Baba, Shibata et al. 2004) between non-synonymous SNV density and 
synonymous SNV density conditional on the intron SNV density. We found that the 
partial correlation is still very significant (Correlation: 0.18, P< 2.2e-16) after 
removing the influence of intron variant density, suggesting that regional mutation 
prevalence fluctuation can only explain part of the correlation between synonymous 
and non-synonymous SNV density. So the correlation between Nd and Sd is more 










Figure 2.2A Mean ns-SNV densities for different quantiles of synonymous SNV 
density. The correlation coefficient between ns-SNV density and synonymous SNV 









Figure 2.2B Dot plot of ns-SNV density versus synonymous SNV density in log scale 
for all genes. The red line is smooth line generated using a linear model. The 









Figure 2.2C Distribution of the mean ns-SNV density and synonymous SNV density 
for different quantiles of intron SNV density. From this distribution we can observe 
correlation between both ns-SNV density and synonymous SNV density with intron 
SNV density. The correlation coefficient between ns-SNV and intron SNV densities 
is 0.37 (P<2.2e-16) and the correlation coefficient between synonymous-SNV and 












Figure 2.2D Dot plot of ns-SNV density (blue) and synonymous SNV density (red) 
versus intron SNV density for all genes. The dark blue line is the trend line for the 
relationship between ns-SNV density and intron SNV density generated by a linear 
model, the dark red line is the trend line for the relationship between synonymous 
SNV density and intron SNV density generated by a linear model. The x-axis is 
truncated at 30 per KB and the y axis is truncated at 20 per KB. The correlation 
coefficient between ns-SNV and intron SNV densities is 0.37 (P<2.2e-16) and the 





ns-SNV densities are restrained by the mRNA expression level 
We examined the most significant determinant of protein evolutionary rate—mRNA 
expression level, to see how it influences the process of non-synonymous variant 
elimination and fixation.  
 
Figure 2.3 shows the relationship between expression level and the density of non-
synonymous and synonymous SNPs. The observed correlation of non-synonymous 
SNV density with expression level is compatible with what various studies have 
found from protein sequence analysis (Krylov, Wolf et al. 2003; Rocha and Danchin 
2004; Subramanian and Kumar 2004; Wright, Yau et al. 2004; Lemos, Bettencourt et 
al. 2005; Drummond, Raval et al. 2006). The population genomics data not only 
provides new supporting evidence that mRNA expression level is a strong 
determinant of selection pressure for protein evolution, but also gives us a way to 
estimate the exact level of constraint caused by expression level. Using a simple 
linear model, we estimate that non-synonymous SNV density will decrease by 
0.18/Kb (see Methods) for each doubling of the expression level, which is roughly 
1/25 of the average ns-SNV density for all genes. We found there is no significant 
correlation between synonymous SNV density and mRNA expression level which is 
at odds with result of a previous study (Drummond and Wilke 2008). 
 
As noted earlier, according to the model of “mistranslation induced mis-folding” 
(Drummond and Wilke 2008), mutations cause protein misfolding, and hydrophobic 




proteins, resulting in aggregation that disrupts cell function. If this mechanism is the 
main selection pressure against the accumulation of non-synonymous changes, we 
expect that the trend of negative correlation between the SNV density of high impact 
variants and mRNA expression will be larger than that between the SNV density of 
low impact variants and mRNA expression. We tested this by dividing non-
synonymous SNVs into two categories: those with an expected high impact on 
protein function and those expected to be neutral by our SNPs3D profile method. We 
found that the correlation to mRNA expression level is slightly stronger for predicted 
high impact SNVs than neutral SNVs (Figure 2.4), consistent with the mistranslation 









Figure 2.3 Mean ns-SNV and synonymous SNV density for different quantiles of 
mRNA expression levels. The ns-SNV density negatively correlates with the 
logarithm of mRNA expression level (Correlation coefficient -0.13, P<2.2e-16). 
There is no significant correlation between synonymous SNV density and logarithm 





Figure 2.4 Mean ns-SNV density of two different categories of ns-SNV 
(red: predicted to be deleterious by SNPs3D, blue: predicted to be neutral by 
SNPs3D) for different quantiles of mRNA expression level. The correlation of log 
mRNA expression level with predicted high impact nsSNV density (correlation 
coefficient: -0.12, P<2.2e-16) is higher than the correlation between the predicted 
neutral nsSNV density (correlation coefficient: -0.08, P<2.2e-16)  
 
ns-SNV densities also correlate with protein network features 
Studies have also found a correlation between the number of protein-protein 
interactions with protein evolutionary rate (Fraser, Hirsh et al. 2002; Fraser, Wall et 
al. 2003; Pal, Papp et al. 2006). This correlation is believed to be caused by protein 




2008) that has been proposed as an explanation for mRNA expression level effects. 
We look at this question at the population level by comparing the SNV densities of 
genes with different number of interactions in a protein function interaction network 
(Wu, Feng et al. 2010). We observe a significant negative correlation between non-
synonymous SNV density and the logarithm of the degree of proteins in the network 
(correlation coefficient: -0.12, P < 2.2e-16) and no significant correlation between 
synonymous SNV density and the logarithm of the degree of proteins in the network 
(correlation coefficient: -0.02, P=0.11). Inspection of the mean ns-SNV density at 
different quantiles of degree (Figure 2.5) shows the first few bars deviating 
substantially from the correlation trend. This probably reflects the effect of variable 
levels of missing interactions in the network. There is also a significant correlation 
between log degree of proteins and the log expression level (correlation coefficient 
0.08, P=2.6e-13), so it’s possible that the correlation between non-synonymous SNV 
density and the log of degree is a byproduct of the correlation between non-
synonymous SNV density and log expression. To resolve this issue, we calculated the 
partial correlation between log degree and non-synonymous SNV density conditioned 
on the log of gene expression levels. We found the partial correlation is very 
significant (correlation coefficient -0.11, P = 1.05e-24). We also calculated the partial 
correlation between non-synonymous SNV density and log expression level 
conditioned on the log degree and also found a significant correlation (correlation 
coefficient -0.13, P<1e-30 ). These results suggest the number of functional 
interactions and the mRNA expression level are two independent forces in shaping 




non-synonymous SNV density will drop 0.21 per Kb for each doubling of functional 
interactions, roughly the same as the drop of ns-SNV density when the expression 
level is doubled. 
 
Figure 2.5 Mean ns-SNV/synonymous SNV density as a function of quantiles for the 
number of protein neighbors in a protein functional network. nsSNV density is 
negatively correlated with the log degree in the network (correlation coefficient -0.12, 
P<2.2e-16), while there is no significant correlation (correlation coefficient -0.02, 





Outlier genes  
There are some genes that clearly do not follow the general trends described above. It 
is of interest to examine them. For the correlation between non-synonymous SNV 
density and mRNA expression level, we pick the 37 genes whose mRNA expression 
is in the top 10% range and ns-SNV density is at least 3 times the average (Figure 
2.6),  and perform a GO enrichment test using Gorilla (Eden, Lipson et al. 2007; 
Eden, Navon et al. 2009). We found these genes are enriched in immune response 
processes (Table 2.1). Diversity in these genes can increase the fitness of the carrier, 
offsetting the fitness cost of potential protein aggregation, so it’s not surprising that 
these genes deviate from the general trend. In a similar analysis of non-synonymous 
SNV density and degree of protein interactions, we pick the 151 genes whose number 
of interactions is in the top 10% range ns-SNV density is at least 3 times the average. 
We found a group of genes with degree around 380 having significantly higher non-
synonymous variant density than other genes of similar degree (Figure 2.7). Upon 
inspection of this group, we found they are all zinc finger proteins and that these form 
an almost complete clique in the functional network. This may be because all these 
proteins bind DNA so the functional interaction network considers them involving in 
a super large complex, resulting in an artificial blowup of their degree values. In 
addition, we found a group of genes with moderately high degree but a very high 
level of ns-SNV density (Figure 2.7). These are all HLA genes, which have functional 
interactions with many T-cell receptors. It’s not surprising these have high diversity 





Figure 2.6 Distribution of ns-SNV density versus mRNA expression. Genes in the 
region highlighted by the oval have very high non-synonymous variant density and 
high expression values, contrary to the general correlation between these variables. 





Figure 2.7 Distribution of ns-SNV density versus degree of protein interactions. 
Zinc finger genes deviate from the negative correlation between these variables. This 




Table 2.1 List of GO Biological Process terms enriched in outliers of the correlation 
between mRNA expression and non-synonymous variant density. 




GO:0009617 response to bacterium 2.96E-13 3.34E-09 32.69 
GO:0051704 multi-organism process 1.12E-10 6.32E-07 6.45 
GO:0051707 response to other organism 3.42E-10 1.29E-06 13.14 
GO:0050832 defense response to fungus 6.26E-10 1.77E-06 110.8 
GO:0009620 response to fungus 4.73E-09 1.07E-05 76.7 
GO:0042742 defense response to bacterium 4.96E-09 9.34E-06 27.64 
GO:0060333 interferon-gamma-mediated signaling pathway 8.15E-09 1.32E-05 39.23 
GO:0009607 response to biotic stimulus 1.67E-08 2.35E-05 9.07 
GO:0044364 disruption of cells of other organism 2.35E-08 2.95E-05 122.73 
GO:0031640 killing of cells of other organism 2.35E-08 2.66E-05 122.73 
GO:0071346 cellular response to interferon-gamma 3.12E-08 3.21E-05 31.49 
GO:0034341 response to interferon-gamma 1.06E-07 9.95E-05 25.73 
GO:0001906 cell killing 4.80E-07 4.18E-04 61.36 
GO:0002480 antigen processing and presentation of exogenous 
peptide antigen via MHC class I, TAP-independent 1.21E-06 9.74E-04 132.95 
GO:0006952 defense response 1.65E-06 1.24E-03 5.12 
GO:0002478 antigen processing and presentation of exogenous 
peptide antigen 2.01E-06 1.42E-03 15.64 
GO:0019884 antigen processing and presentation of exogenous 
antigen 2.16E-06 1.44E-03 15.44 
GO:0048002 antigen processing and presentation of peptide antigen 3.11E-06 1.95E-03 14.5 
GO:0016045 detection of bacterium 4.08E-06 2.43E-03 92.05 
GO:0035821 modification of morphology or physiology of other 
organism 5.06E-06 2.86E-03 34.68 
GO:0019882 antigen processing and presentation 6.02E-06 3.24E-03 12.94 
GO:0009595 detection of biotic stimulus 2.48E-05 1.27E-02 52.03 
GO:0007565 female pregnancy 3.22E-05 1.58E-02 21.86 
GO:0019221 cytokine-mediated signaling pathway 6.14E-05 2.89E-02 8.58 
GO:0044703 multi-organism reproductive process 7.81E-05 3.53E-02 5.48 






1000 genomes project data 
The 1000 genomes data (Durbin, Altshuler et al. 2010) was downloaded from 
http://www.1000genomes.org/data. The 2010 November data set (Phase I) is used. 
Only variants that passed all quality filters are accepted for this study. The 
synonymous, non-synonymous and intron variants are annotated using gene 
coordinate information from Refseq (Pruitt, Tatusova et al. 2007) genes downloaded 
from UCSC genome browser (Fujita, Rhead et al. 2011) http://genome.ucsc.edu/ in 
Jan 2012. We get 133,103 synonymous, 177,191 non-synonymous and 1,2511,175 
intron variants respectively. These numbers are smaller than those in (Abecasis, 
Auton et al. 2012) because we use Refseq annotation which is more conservative than 
the gencode annotation (Harrow, Frankish et al. 2012) used in that study. Only 30% 
of gencode transcripts are also included in Refseq annotation. 
(http://gencodegenes.wordpress.com/2013/01/08/comparing-different-publicly-
available-genesets-against-gencode-7/). We calculated the allele frequency for each 
of the variants by dividing the number of alleles (count 1 for heterozygous and 2 for 
homozygous) with that variant by the total number of allele positions (2 times the 
total number of people). We first calculated the allele frequency for each ethnic 
group, and then we took the average over these to obtain the overall average allele 
frequency for that variant. The density of non-synonymous SNVs and the density for 
synonymous SNVs for each gene are calculated by dividing the number of 




SNVs for a gene is calculated by dividing the number of single base variants in 
introns of that gene by the total base length of introns of that gene. For each NCBI 
gene ID, we randomly pick one isoform for the calculation if multiple isoforms are 
available. 
 
Human mRNA expression data 
The Human mRNA expression data for 79 human tissues (Su, Wiltshire et al. 2004) 
was  downloaded from http://biogps.org/downloads/. For each gene, the maximum 
expression level across all tissues was extracted for this study.  
 
SNV impact prediction 
We use our SNPs3D profile method (Yue and Moult 2006) to predict the impact of 
the non-synonymous variants. We were able to make predictions for 145,336 of the 
non-synonymous variants, covering roughly 80% of all the high reliability non-
synonymous SNVs annotated in this study. The SNPs3D predictor returns a SVM 
score for each variant. The more negative the score, the more likely that the variant 
has a high impact. In the study of relationship between SNV impact and SNV 
frequency, we annotate those SNVs with negative SVM score as predicted deleterious 





Human Protein Functional Interaction Network 
The Human protein functional interaction network (Wu, Feng et al. 2010) was 
downloaded from http://genomebiology.com/content/supplementary/gb-2010-11-5-
r53-s3.zip on April 2012. The functional interaction set, FI, is used in this study, and 
consists of both experimental data and predictions. The network contains both curated 
functional interactions from biological pathway databases such as Reactome 
(Matthews, Gopinath et al. 2009) and KEGG (Kanehisa and Goto 2000) and 
functional interactions based on high throughput experimental data such as protein-
protein physical interactions, yeast two hybrid, gene co-expression. 
 
Partial correlation 
Pearson partial correlations in this study are calculated using the R package ppcor 
(Kim and Yi 2006) with variance-covariance matrix inversion option. 
 
Quantitative estimation of the selection pressure caused by mRNA expression level and 
number of functional interactions 
We use a simple linear model to fit the relation between non-synonymous variant 
density and logarithm of mRNA expression level and logarithm of functional 
interactions: The formula is: 
E 




could be either mRNA expression level or the number of interactors in the functional 
interaction network. 
 
GO enrichment analysis of outliers 
The GO enrichment analysis was performed on the Gorilla (Eden, Navon et al. 2009) 
website http://cbl-gorilla.cs.technion.ac.il/. The “Two unranked lists of genes” mode 
was used.  
 
2.4: Discussion 
In this study, we addressed a series of questions in evolutionary biology using 
population genomics data from the 1000 genomes study (Durbin, Altshuler et al. 
2010). We first looked at the relationship between the frequency of SNVs and their 
predicted impact on protein function. We observed that the fraction of predicted 
deleterious ns-SNVs among all ns-SNVs drops as the population frequency increases. 
This is as expected from the theory of purifying selection (Akey, Zhang et al. 2002) 
and similar results have been shown in the 1000 genome exon pilot project (Marth, 
Yu et al. 2011). 
 
Using population genomics data, we can not only analyze variant distributions in 
coding regions but can also study intron divergence, providing a better reference set 
of SNVs under near-zero selection. Based on partial correlation analysis of the 




synonymous SNV density, we propose that the correlation between synonymous and 
non-synonymous variant density is the outcome of the combined effect of shared 
selection pressure at synonymous and non-synonymous sites, and the variation of 
local mutation prevalence across the genome. We expect that the correlation between 
dS and dN is largely for the same reasons.  
 
We then look at two factors that are tightly coupled to the protein evolutionary rate: 
mRNA expression level and number of interactions in the protein network. We found 
the corresponding population genomics measure of dN, the non-synonymous SNV 
density, negatively correlates with mRNA expression level. The correlation is 
stronger for SNVs that have predicted high impact on protein function. The predictor 
is trained on monogenic disease causing mutations from the HGMD (Stenson, Ball et 
al. 2003) database. Our previous studies have shown that loss of protein stability is a 
major cause (approximately 75% of mutations) of monogenic disease. So most high 
impact predictions are expected to be SNVs with high structural impact, related to 
misfolding and/or stability loss. This is consistent with the mistranslation-induced-
misfolding model proposed by Drummond and Wilke (Drummond and Wilke 2008), 
which argues the selection pressure on non-synonymous sites is largely caused by the 
nasty consequences of protein mis-folding. By analyzing the relationship between 
non-synonymous SNV density and mRNA expression level, we can quantitatively 
estimate how this biophysical restraint influences the pattern of variant. Using a 
simple linear model, we estimate the non-synonymous variants density drops 0.18 




doubling of expression level. 
 
We did not observe a correlation between synonymous SNV density and the mRNA 
expression level, which is at variance with the results from  inter-species analysis, 
since a correlation between dS and mRNA expression rate has been reported in 
(Drummond and Wilke 2008). Three factors may contribute to this difference: 1) The 
SNV density only counts the number of distinct SNVs in the region of a gene but 
doesn’t consider the population frequency of these variants, which contains important 
information for the selection pressure of the corresponding sites. In practice, the data 
are dominated by SNVs with a frequency of less than 0.5%, reducing the selection 
diversity.  2) We find that the correlation coefficient between non-synonymous 
variant density and mRNA expression level is about two fold smaller than correlation 
between dN and mRNA expression level (-0.13 vs -0.2~-0.25 for prefrontal cortex) 
reported in previous studies (Drummond and Wilke 2008). Since the correlation 
between dS and mRNA expression level (-0.1) is much weaker than the correlation 
between dN and mRNA expression level (-0.2~-0.25), the correlation between 
synonymous variants density and mRNA expression may be too low to be detected. 
Results from the recent whole genome sequencing of 21 breast cancers (Nik-Zainal, 
Alexandrov et al. 2012) show that the cancer somatic mutation rate is also correlated 
with the mRNA expression level.  The same pattern has also been found in malignant 
melanoma and a small cell lung cancer (Pleasance, Cheetham et al. 2010; Pleasance, 
Stephens et al. 2010). It has been proposed  (Nik-Zainal, Alexandrov et al. 2012)  that 




more effectively to highly transcribed genes. This mechanism may not play an 
important role in the negative correlation we observed from population genomics 
data. Otherwise, we would also see correlation between synonymous variants and 
mRNA expression level because the NER doesn’t differentiate non-synonymous 
versus synonymous sites. Further studies are required to understand the difference 
between the mutation accumulation process in cancer cells and in human populations. 
 
The observed negative correlation between protein-protein functional interactions and 
non-synonymous SNV density demonstrates that the number of interactions of a 
protein impose selection on its non-synonymous sites. The selection could be because 
highly connected genes play a central role in the biological system, so that they are 
less likely to accept non-synonymous mutations (Wuchty 2004). Another explanation 
is that a larger proportion of the amino acids in highly connected genes are directly 
involved in the protein-protein contacts, thus they are subject to constraint caused by 
their interaction partners (Fraser, Hirsh et al. 2002). We estimate that the non-
synonymous SNV density will drop 0.21 per Kb when the number of functional 
interactions is doubled, and the selection pressure is independent of that caused by 
mRNA expression level. 
 
The work described here makes use of just 1000 genomes. Many more genomes are 
becoming available, and these will lead to more accurate calculation of variant 
density and hence more reliable determination of the factors discussed. For example, 




exon sequences for 2440 individuals at an average depth of 111X and again found 
there are large quantities of rare SNVs in the human exome, most of which were 
previously unknown. Another recent study (Fu, O’Connor et al. 2012) sequenced 
6,515 individuals of European American and African American ancestry and inferred 
the age of 1,146,401 autosomal single nucleotide variants (SNVs). All these 
upcoming studies will help us know more about the evolutionary process of human 
SNVs, their origin, history, and the forces that determine their fate. These questions 
are of great interest for basic research and also important for variant-diseases studies 
(Do, Kathiresan et al. 2012). We hope with more data becoming available, we can 
















Chapter 3: GWAS and drug targets 
3.1: Introduction 
Until recently, information on which variants within the human genome contribute to 
increased risk of common human disease was fragmentary and often statistically 
weak. New chip-based technologies and large-scale sequencing have now provided 
relatively unbiased and reliable information on SNVs (single nucleotide variants) and 
indels significantly associated with altered risk for a number of common diseases.  To 
date, most information has been obtained through genome wide association studies 
(GWAS) using microarray technology, providing information only on common SNVs 
(the single nucleotide polymorphisms, SNPs). The current generation of GWA studies 
typically include several thousand individuals with the disease of interest and a 
similar number of control individuals without the disease, and in total, more than 
1600 loci where variants are associated with complex traits have been discovered (the 
GWAS catalog, http://www.genome.gov/gwastudies) 
 
There have been a number of discussions about the efficacy of GWA studies (Corvin, 
Craddock et al. 2010). In spite of the success in discovering disease associations, it is 
becoming clear that many mechanism genes with the highest effect on disease 
phenotypes are not discovered by GWAS. Studies of blood pressure provide a 
striking example. There is a long history of identification of genes affecting blood 
pressure using non-genomic methods, and 30 genes discovered in this way have 




2011). But only a few of these candidate genes and no drug targets are discovered in 
GWAS (Ehret 2010). Limited coverage of current microarrays only explains a 
fraction of these missing genes (Sober, Org et al. 2009). Further, mouse knockout 
data suggest that some of the missing genes have very large effect sizes, with blood 
pressure changes of 10s of mm of Hg (Takahashi and Smithies 2004), whereas the 
largest changes associated with marker SNPs in GWAS studies are between about 0.5 
and 1 mm of Hg (Takahashi and Smithies 2004), 
 
Known drug targets - genes that have a large effect size on the corresponding disease 
phenotype, and so should be found by GWAS – provide a means of investigating 
whether non-discovery of mechanism genes is a general phenomenon. In this project, 
we compared a set of reported mechanism genes in the GWAS catalog 
(www.genome.gov/gwastudies (Hindorff, Sethupathy et al. 2009), January 2012) with 
a corresponding set of known drug target genes (obtained from Drugbank (Knox, 
Law et al. 2011), January 2012) for the same diseases and found the overlap is very 
low. We also investigated two possible explanations for the low overlap between 
these two sets of genes and discussed the relationship between these two sets of 
genes. Finally, we considered the relationship between GWAS genes and drug targets 
in the context of a protein functional interaction network, and developed a machine 
learning method to predict new drug targets using the relationship between GWAS 






Comparison of the GWAS catalog and Drugbank shows GWAS only detects a very 
small fraction of existing drug targets. 
We examined the relationship between genes in the GWAS catalog (Hindorff, 
Sethupathy et al. 2009) and drug target genes in Drugbank (Knox, Law et al. 2011). 
The GWAS catalog (http://www.genome.gov/gwastudies/) is a comprehensive 
collection of results from published GWAS studies on a wide variety of disease and 
other traits such as height. Drugbank (Knox, Law et al.) is a database that combines 
detailed drug (i.e., chemical, pharmacological and pharmaceutical) data with 
comprehensive drug target information (sequence, structure, and pathway). We 
compiled a list of diseases in the GWAS catalog and extracted the reported genes for 
each of them. We then found the drugs used in treatment of these diseases in 
Drugbank, and extracted the drug target genes for each drug. Thus, for each disease, 
we have a list of GWAS reported genes and a list of drug targets. For the 88 GWAS 
diseases that have drugs in Drugbank, there are on average 29.2 GWAS reported 
genes and 24.0 drug targets for 19.9 drugs (Table 3.1). In total, only 20 of 856 drug 
target genes are discovered in GWAS studies of the same disease. This is slightly 
larger than the estimated overlap of 5 from a completely random model, but still is a 
very low number if we expect the two sets of genes are related to each other.  In 
Drugbank, some drug targets do not have a known mechanism and are probably 
“predicted” drug targets based on sequence similarity to the verified drug targets 




compiled a list of verified drug targets all of which have known drug action 
mechanisms documented in Drugbank. We find similar results to those for the 
complete list of drug targets. For those 353 drug targets for 81 diseases with known 
mechanisms and with corresponding GWAS studies, only 12 are discovered by 
GWAS (Table 3.2). On average, there are 30 GWAS reported genes and 11.2 verified 
drug targets for each of these 81 diseases. 
 









GWAS overlap, all 
diseases 
       
Acute lymphoblastic 
leukemia 
6 19 10 0 3 
Age-related macular 
degeneration 
9 23 2 1 2 
Allergic rhinitis 69 11 20 0 5 
Alzheimer's disease 5 54 179 0 40 
Amyotrophic lateral sclerosis 3 26 2 0 1 
Ankylosing spondylitis 39 17 29 0 9 
Arthritis 168 7 112 0 35 
Asthma 102 43 52 1 19 
Atopic dermatitis 12 8 3 0 1 
Atrial fibrillation 45 7 25 0 14 
Attention deficit hyperactivity 
disorder 
3 81 1 0 1 
Autism 3 6 10 0 5 
Basal cell carcinoma 6 8 9 0 2 
Bipolar disorder/ 
Schizophrenia 






351 100 114 3 35 
Breast cancer 84 42 43 1 13 
Celiac disease 3 74 1 0 0 
Chronic kidney disease 8 69 6 0 2 
Chronic lymphocytic 
leukemia 
14 17 29 0 5 
Chronic myeloid leukemia 6 9 15 0 6 
Chronic obstructive 
pulmonary disease 
14 18 7 0 2 
Colorectal cancer 8 14 16 0 6 
Coronary heart disease 6 84 5 0 3 
Crohn's disease 7 136 23 0 9 
Cystic fibrosis 8 7 11 0 5 
Depression/ 
Depressive disorder 
45 68 73 0 17 
Diabetes 46 205 59 4 21 
Duodenal ulcer 8 2 18 0 5 
Emphysema 10 5 17 0 5 
Endometrial cancer 1 2 2 0 0 
Endometriosis 5 4 7 0 3 
End-stage renal disease 2 2 8 0 3 
Epilepsy 18 1 53 0 10 
Esophageal cancer 1 18 2 0 1 
Gallstones 1 1 1 0 0 
Gastric cancer 2 3 1 0 0 
Glaucoma 24 13 31 0 6 
Glioblastoma 2 1 1 0 0 
Heart failure 51 16 65 0 27 
HIV/AIDS 54 62 53 1 9 
Hodgkin's lymphoma 8 7 31 0 7 
Hypertriglyceridemia 2 5 4 0 3 
Hypothyroidism 5 43 8 1 5 




Kawasaki disease 1 20 11 1 5 
Malaria 17 3 17 0 4 
Male infertility 6 5 3 0 3 
Melanoma 9 20 6 0 0 
Menopause 9 23 15 0 4 
Migraine 20 7 46 0 10 
Multiple myeloma 7 3 10 0 3 
Multiple sclerosis 10 123 30 1 12 
Myocardial infarction 29 14 44 0 17 
Narcolepsy 2 4 6 0 1 
Nephropathy/ 
Nephrotic syndrome 
20 26 38 0 9 
Neuroblastoma 2 2 6 0 2 
Non-small cell lung cancer 5 7 10 0 1 
Obesity 4 40 11 0 4 
Osteoarthritis 26 3 46 0 10 
Osteoporosis 13 10 10 0 2 
Ovarian cancer 5 10 4 0 1 
Paget's disease 4 9 6 0 1 
Pancreatic cancer 2 29 11 0 4 
Panic disorder 6 10 18 0 4 
Parkinson's disease 20 62 184 1 34 
Polycystic ovary syndrome 2 7 2 0 1 
Prostate cancer 14 94 21 0 8 
Psoriasis/Psoriatic arthritis 19 30 39 0 13 
Refractive error 1 4 4 0 1 
Restless legs syndrome 2 6 18 0 6 
Rheumatoid arthritis 46 67 80 2 29 
Sleepiness 1 2 2 0 0 
Stevens-Johnson syndrome/ 
toxic epidermal necrolysis 
1 12 1 0 0 
Stroke 8  4 7 0 6 
Tardive dyskinesia 3 1 22 0 7 




Thyroid cancer 2 5 3 0 2 
Tuberculosis 12 5 18 0 4 
Type 1 diabetes 8 74 18 0 8 
Type 2 diabetes 28 91 34 3 13 
Ulcerative colitis 5 95 9 1 6 
Uterine fibroids 1 7 1 0 0 
Venous thromboembolism 1 7 3 0 2 
Vitiligo 4 25 8 1 2 
Mean 19.90 29.18 24.00 0.26 7.09 
 
Analysis using 1000 genomes project data shows Drug Target genes have  fewer high 
frequency deleterious non-synonymous SNPs than GWAS reported genes  
We next consider why GWAS identifies so few known drug targets. A study of all the 
SNPs in the GWAS catalog (Hindorff, Sethupathy et al. 2009) shows that reported 
SNPs are common (median risk allele frequency 36%, interquantile range (IQR) 
21%-53%), and are associated with modest effect size (median odds ratio 1.33, IQR 
1.20-1.61 ).  
 
We speculated that drug target genes escape GWAS studies because they contain few 
common SNPs with negative effect. To test this hypothesis, we look at the 
distribution of SNP frequencies and SNP effect size in GWAS identified genes and 
drug targets. SNP frequencies were calculated from 1000 genomes project (Durbin, 
Altshuler et al. 2010) data. 
 




different mechanisms (altering protein sequence, altering the regulation of the 
expression of genes, changing the splicing pattern, changing the stability of 
messenger RNA). We focus our investigation on non-synonymous SNPs for two 
reasons: 1) A study has shown that reported SNPs are significantly overrepresented in 
non-synonymous sites (Hindorff, Sethupathy et al. 2009). 2) There are a number of 
computational methods to estimate the effect of non-synonymous SNPs on in vivo 
protein function, with useful accuracy (Ng and Henikoff 2003; Yue, Melamud et al. 
2006; Bromberg and Rost 2007; Adzhubei, Schmidt et al. 2010). We calculated the 
frequency of all the non-synonymous SNPs in GWAS identified genes and drug 
targets, and then predicted the effect of these SNPs using two methods, the SNPs3D 
profile method (Yue and Moult 2006) and PolyPhen2 (Adzhubei, Schmidt et al. 
2010). We found the drug targets genes do have fewer non-synonymous SNPs 
(0.0155/aa. vs. 0.0171/aa.) and the tendency is more significant for common (Allele 
frequency > 5%) non-synonymous SNPs (0.00169/aa. vs. 0.00221/aa, Mann-Whitney 
test P=0.0017). For ns-SNPs with a predicted negative effect, there is also significant 
difference between these two set of genes. The fraction of predicted negative effect 
ns-SNPs among all common ns-SNPs is smaller for drug targets than GWAS reported 
genes (15.8% vs. 19.2%).  A possible explanation for the low occurrence of common 
high impact SNPs is that the activity level of drug targets genes is strongly coupled to 
the disease phenotype. As a result they are under relatively high selection pressure, 
and SNPs with a substantial impact on function will be eliminated or tend to be at a 
low frequency. We expect this rule applies to both non-synonymous SNPs and other 





Table 3.3 Comparison of non-synonymous SNP distribution between GWAS reported 
genes and drug targets 
 Drug Targets GWAS reported genes All genes 
    
Density of Non-
synonymous SNPs 
0.0155 0.0171 0.0171 









Fraction of Common 
deleterious Non-
synonymous SNPs 


















P-value for Mann-Whitney test against the density of common non-synonymous SNPs for 
GWAS reported genes.  
2
P-value for Mann-Whitney test against the density of common non-
synonymous SNPs for all genes.   
 
Evolutionary analysis shows drug target genes are under slightly stronger negative 
selection than GWAS reported genes  
If the drug targets genes are under stronger selection as we proposed, we should 
observe it through evolutionary analysis. dN/dS (Kimura 1977) is a measure of 
selection pressure on genes. We compared the dN/dS for these two set of genes using 




stronger selection (Table 3.4) than all genes. We also looked at the selection effect on 
monogenic disease genes from the HGMD database (Stenson, Ball et al. 2003)  which 
are considered to be under negative selection because mutations in those genes cause 
disease. We found HGMD genes are also under negative selection in recent history 
(dN/dS calculated using human-chimp orthologs). The selection against variants in 
drug target genes is slightly stronger than that against variants in GWAS reported 
genes (Table 3.4) for dN/dS calculated using Human-chimp orthologs, suggesting the 
selection is stronger for drug targets in recent history. 
  
Table 3.4 dN/dS analysis for GWAS reported genes and drug targets 
 




P Value for 
Mann-Whitney 
test against all 
genes 
P Value for 
Mann-Whitney 
test against gwas 
reported genes 
      
Human-Mouse 
orthologs 
All genes 13691 0.22   
GWAS reported genes 2932 0.19 2.44e-09*  
Drug targets 1035 0.18 1.21e-04* 0.43 
Drug targets with known 
mechanism 
432 0.17 6.04e-06* 0.038* 




All genes 14173 0.44   
GWAS reported genes 2911 0.36 1.26e-13*  
Drug targets 1020 0.33 2.78e-13* 0.0098* 
Drug targets with known 
mechanism 
423 0.32 4.2e-8* 0.013* 




The influence of transcript length 
We also examined an additional possible reason why GWAS does not identify known 
drug targets. Suppose the mechanism SNPs are distributed randomly across the 
relevant genes, then the chance of a gene being identified should be related to its 
length.  
 
A disease by disease analysis shows that for most of the diseases the GWAS reported 
genes are significantly longer than the drug target genes (paired Mann-Whitney test, 
P=1.89e-6) and in general GWAS reported genes tend to be longer than drug target 
genes and longer than all other genes (Figure 3.1). The mean longest transcript length 
for GWAS reported genes is about 110K while the mean longest transcript length for 
drug targets is about 60K. 
 
Thus, these two factors, a tendency for GWAS genes to be longer than drug targets, 
and a lower density of common SNPs in drug targets at least partially explain the 








Figure 3.1 Distribution of the log longest transcript length for different types of 
genes. 
 
Network analysis shows GWAS reported genes are close to drug target genes in a 
biological network 
Although most drug targets are not identified through GWAS studies, they are 
obviously as much involved in the disease mechanism as GWAS genes, and so will 
have similar properties, particularly in terms of pathway and network relationships. A 
number of studies have incorporated network information to aid in identifying various 
classes of genes, for example using a network module formalism to combine signals 




network flow models to predict drug targets from expression and other data in 
prostate cancer (Yeh, Yeh et al. 2012). Network models have also been used to 
identify pathways implicated in cancer (Ciriello, Cerami et al. 2012). It has already 
been observed that GWAS genes are substantially more closely connected in a 
functional network (Rossin, Lage et al. 2011) than random genes, and we expect that 
to be the case for other large effect genes, such as known drug targets.  
 
There are many resources available for different types of human biological networks. 
Protein-Protein interaction data (Chatr-aryamontri, Ceol et al. 2007; Breitkreutz, 
Stark et al. 2008) have a wide coverage but usually have a high false positive rate. 
Curated pathways like KEGG (Kanehisa 2002; Kanehisa, Goto et al. 2002; Kanehisa, 
Goto et al. 2004) and BioCarta (http://www.biocarta.com/genes/index.asp) are 
considered to be accurate but the coverage is sparse (Wu, Feng et al. 2010). Networks 
built from other kinds of relationship such as  regulatory networks deduced from 
micro-array data (Lee, Hsu et al. 2004; Prieto, Risueno et al. 2008) or networks based 
on biochemical reactions (Lang, Stelzer et al.) are too narrow in terms of the 
interactions they capture. 
 
In this study, we use the Functional Interaction (FI) network from(Wu, Feng et al. 
2010) , which is a protein functional interaction network generated by extending 
curated biological pathways with non-curated sources of information, including 
protein-protein interactions, gene co-expression, protein domain interaction, Gene 




50% of the human genes. The network strikes a balance between experimentally 
validated results and prediction, with the prediction part benchmarked by a 
reasonably rigorous process. We were able to map 611 out of 821 drug targets genes 
and 1125 out of 1914 GWAS reported genes for the 88 diseases to the network.  
 
Examination of the network proximity of GWAS genes to each other and to drug 
targets for the same disease indeed shows a strikingly close-nit matrix of 
relationships. Figure 3.2 shows the network formed for the 43 GWAS and 16 drug 
target genes (Knox, Law et al. 2011) for Type I Diabetes that project onto the FI 
network, and only including genes from these two sets which are linked by not more 
than one other intermediate gene. All drug targets and all but five of the GWAS genes 
form part of a single continuous sub-network.  
 
This suggests that the two sets of genes are relatively close in their biological 
function. One way to look at the relationship between GWAS reported genes and 
drug target genes is to measure how close each GWAS gene is to its nearest drug 
target (Figure 3.3). Different drug targets may be involved in different mechanisms, 
so that a GWAS gene may be very close to one drug target while further from others. 
The distributions show that the distances from a GWAS reported gene to the closest 
drug target are on average much shorter than those of a random gene to a closest drug 
target, and the shortest distance from a drug target gene to the closest GWAS reported 
gene is also shorter than that of a random gene to the closest GWAS reported gene. 




and are also enriched in GWAS second neighbors (genes two steps away in the gene 
network) (Figure 3.3). 
 
Highly connected genes have more neighbors, and thus are more likely to include 
GWAS genes as neighbors. Thus, the observed enrichment of short paths between 
drug targets and GWAS genes could partially be a consequence of higher 
connectivity for drug targets. To control for this effect, we compared the degrees of 
drug targets with all genes (Figure 3.3C), and we found drug targets have a slightly 
higher level of degree (Mann-Whitney test, P = 0.014) on average. However the 
difference is marginal, and is unlikely to significantly contribute to the substantial 





Figure 3.2 Network for GWAS gene and drug targets of Type I Diabetes 
Continuous network substructure formed by 43 of the 74 GWAS (green) and 16 of 
the 18 drug targets (red) for Type 1 Diabetes, allowing not more than one 
intermediate gene (grey). GWAS and drug target genes are intermingled in the 
network, and short paths are sufficient to form a connected network for almost all 
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target
Random gene to nearest Drug
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Figure 3.3A The distribution of shortest distance to the nearest drug target for GWAS 

























Drug target to nearest GWAS
gene
All gene to nearest GWAS
gene
 Figure 3.3B The distribution of the shortest distance to the nearest GWAS genes for 






Figure 3.3C Distribution of degree for drug targets and all genes in the FI network. 
The drug targets have a slightly higher level of degree (Mann-Whitley test P = 0.014). 
The difference is marginal, and does not explain the observed enrichment of drug 
targets in the first neighbor of GWAS reported genes.   
 
Machine learning method for drug target discovery 
The strong relationship between drug targets and GWAS gene revealed in the 
network analysis led us to think about ways to identify drug targets from GWAS 
genes using machine learning methods based on network features. The idea is to 
evaluate the probability that any gene is a potential drug target, given its network 
environment. Since we observed a threefold enrichment of drug targets in the first 




a feature. This quantity is highly dependent on the total number of neighbors a gene 
has, so we also use the degree of the gene as a control. As the previous analysis 
shows, second neighbors of drug targets genes (genes that are two steps away in the 
protein interaction network) are also enriched for GWAS genes, thus we also use the 
number of GWAS genes in the second neighbors of the genes as a feature. These 
three features capture the enrichment information from our previous analysis, but 
there are some subtle relationships not included. The problem of identifying drug 
targets is very similar to the problem of finding missing relationships in social 
network analysis.  We therefore also use common friends with GWAS genes, a 
widely used feature in the social network machine learning field (Fire, Tenenboim et 
al. 2011). The common neighbor feature is defined as the proportion of neighbors 
shared by two genes: 
 
In which NA is the set of Neighbors for gene A, NB is the set of Neighbors for gene B.  
 
The total number of features for each gene is 3+N, where N is the number of GWAS 
genes for that disease that are mapped to the protein network.  Since the number of 
drug targets (average 30) for a disease is very small compared to the total number of 
genes in the FI network (10956), the training set is highly unbalanced if we use the 
latter as the true negative set. To address this issue, we focus on the 932 existing drug 




identifying existing drugs that can potentially be repurposed to treat other diseases. 
Repurposing is an attractive goal, since such use is much easier than developing a 
new drug from scratch (Carley 2005).  
 
We include the 30 diseases with at least 10 approved drug targets and 10 GWAS 
genes in the FI network. We tested four machine learning methods using the WEKA 
software package (Witten, Frank et al. 1999): a SVM with a polynomial kernel, a 
SVM with RBF kernel, a Naïve Bayes Network, and Random Forests. Among these 
we found the best result is achieved by a Random forest (Table 3.5). The best case is 
Kawasaki disease, with a true positive rate of 70% (recovering seven out of 10 known 
drug targets) and a false positive rate of 2.7%.  
 
















17 29(24) 0.36 0.123 0.074 0.36 0.73 0.123 
Menopause 24 15(14) 0.571 0.098 0.082 0.571 0.819 0.143 
Multiple sclerosis 126 30(28) 0.393 0.052 0.19 0.393 0.75 0.256 
Myocardial 
infarction 
14 44(40) 0.175 0.135 0.055 0.175 0.571 0.084 
Nephropathy/Nephr
otic syndrome 
26 38(35) 0.371 0.245 0.056 0.371 0.576 0.097 
Obesity 40 11(11) 0.273 0.098 0.032 0.273 0.724 0.058 




Pancreatic cancer 29 11(6) 0.167 0.1 0.011 0.167 0.611 0.02 
Panic disorder 10 18(16) 0.438 0.118 0.061 0.438 0.754 0.107 
Parkinson's disease 62 184(132) 0.606 0.226 0.307 0.606 0.712 0.407 
Asthma 43 52(47) 0.213 0.102 0.1 0.213 0.713 0.136 
Prostate cancer 95 21(18) 0.5 0.073 0.118 0.5 0.686 0.191 
Psoriasis/Psoriatic 
arthritis 
31 39(36) 0.5 0.076 0.209 0.5 0.852 0.295 
Rheumatoid 
arthritis 
67 80(68) 0.324 0.131 0.163 0.324 0.677 0.217 
Type 1 diabetes 76 18(16) 0.25 0.104 0.04 0.25 0.631 0.07 








101 114(102) 0.412 0.143 0.261 0.412 0.717 0.319 




17 29(26) 0.423 0.098 0.11 0.423 0.653 0.175 




19 10(10) 0.7 0.07 0.097 0.7 0.889 0.171 
Crohn's disease 139 23(22) 0.455 0.093 0.105 0.455 0.764 0.171 
Depression/Depres
sive disorder 
68 73(62) 0.597 0.172 0.198 0.597 0.722 0.297 
Diabetes 209 59(51) 0.216 0.081 0.134 0.216 0.712 0.165 
Allergic rhinitis 11 20(19) 0.263 0.128 0.041 0.263 0.589 0.071 
Glaucoma 14 31(25) 0.16 0.189 0.023 0.16 0.443 0.04 
Alzheimer's disease 54 179(125) 0.544 0.178 0.321 0.544 0.69 0.404 
Heart failure 16 65(54) 0.481 0.222 0.118 0.481 0.655 0.189 




Kawasaki disease 20 11(10) 0.7 0.027 0.219 0.7 0.919 0.333 
 
Potential new drug targets for drug repurposing 
The “false positive” drug targets are those drug targets for other diseases which have 
very similar network properties to those for the disease under study. These may 
indeed be mistakes made by the classifier. However, a more optimistic view would be 
that some of these “false positive” drug targets are good candidates for repurposing, 
not discovered before. 
 
For example, at the top of the false positive list for the best case, Kawasaki disease, 
we found C1QB and C1QC, both subcomponents of complement C1Q. C1Q has been 
shown to be associated with lupus erythematous (Bowness, Davies et al. 1994; Korb 
and Ahearn 1997; Walport, Davies et al. 1998), which is another autoimmune disease 
closely related to Kawasaki disease (Laxer, Cameron et al. 1988; Diniz, Almeida et 
al. 2012).  C1Q is the target of several FDA approved drugs, for example, Etanercept, 
a drug treating rheumatoid arthritis and Adalimumab, a drug treating rheumatoid 
arthritis, psoriatic arthritis, ankylosing spondylitis, and other immune system 
mediated diseases.  Thus these drugs may be potential candidates for use against 
Kawasaki disease.  
 
Another disease where the method performs well is acute lymphoblastic leukemia, 




long list of “false positive” targets (Table 3.6). Careful inspection of these genes 
reveals some that may have relevance to acute lymphoblastic leukemia, and so drugs 
for which they are targets provide potential candidates for repositioning. For example, 
chromosomal aberrations (chromosome translocation) involving FGFR1 are 
associated with stem cell myeloproliferative disorder and stem cell leukemia 
lymphoma syndrome (provided by RefSeq, Jul 2008).  FGFR1 is the drug target of 
Palifermin, which is a recombinant human keratinocyte growth factor (KGF) for the 
treatment of oral mucositis associated with chemotherapy and radiation therapy. It’s 
also the drug target for several experimental drugs. 
 
 Previous studies found differential expression of the oncogene RET in acute myeloid 
leukemia (Gattei, Degan et al. 1998), a distinct but related leukemia. In the version of 
Drugbank used in this analysis, there is no drug targeting RET for the treatment of 
acute lymphoblastic leukemia.  Recently, however, the drug Ponatinib has been 
approved by FDA for treatment of Philadelphia chromosome positive acute 
lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine 
kinase inhibitor therapy. Thus, one of the suggested drug target has been confirmed, 
although for use with a new drug. 
 
Table 3.6 Top “false positive” drug targets for acute lymphoblastic leukemia. 





MAPK3 The protein encoded by this gene is a member of the MAP kinase family. 
MAP kinases, also known as extracellular signal-regulated kinases (ERKs), 
act in a signaling cascade that regulates various cellular processes such as 
proliferation, differentiation, and cell cycle progression in response to a 
variety of extracellular signals. 
1 
PIK3R1  Phosphatidylinositol 3-kinase plays an important role in the metabolic 
actions of insulin, and a mutation in this gene has been associated with 
insulin resistance.  
0.96 
RAF1 v-raf-1 murine leukemia viral oncogene homolog 1 0.96 
EGFR Mutations in this gene are associated with lung cancer. Multiple alternatively 
spliced transcript variants that encode different protein isoforms have been 
found for this gene 
0.96 
FGFR2 Mutations in this gene are associated with Crouzon syndrome, Pfeiffer 
syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, 
Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and 
syndromic craniosynostosis. 
0.96 
KDR This receptor, known as kinase insert domain receptor, is a type III receptor 
tyrosine kinase. Mutations of this gene are implicated in infantile capillary 
hemangiomas. 
0.94 
FLT1 This protein binds to VEGFR-A, VEGFR-B and placental growth factor and 
plays an important role in angiogenesis and vasculogenesis. 
0.94 
FGFR1 Chromosomal aberrations involving this gene are associated with stem cell 
myeloproliferative disorder and stem cell leukemia lymphoma syndrome. 
0.94 
IL2RG The protein encoded by this gene is an important signaling component of 
many interleukin receptors 
0.92 
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene homolog   
0.92 
FGFR3 This particular family member binds acidic and basic fibroblast growth 
hormone and plays a role in bone development and maintenance. Mutations 
in this gene lead to craniosynostosis and multiple types of skeletal 
dysplasia. 
0.9 
AKT1 v-akt murine thymoma viral oncogene homolog 1 0.9 




IL2RA Mutations in this gene are associated with interleukin 2 receptor alpha 
deficiency. 
0.9 
SDC2 The syndecan-2 protein functions as an integral membrane protein and 
participates in cell proliferation, cell migration and cell-matrix interactions via 
its receptor for extracellular matrix proteins. Altered syndecan-2 expression 
has been detected in several different tumor types. 
0.88 
MAPK1 The protein encoded by this gene is a member of the MAP kinase family. 
MAP kinases, also known as extracellular signal-regulated kinases (ERKs), 
act as an integration point for multiple biochemical signals, and are involved 
in a wide variety of cellular processes such as proliferation, differentiation, 
transcription regulation and development.  
0.86 
CD247 The protein encoded by this gene is T-cell receptor zeta, which together 
with T-cell receptor alpha/beta and gamma/delta heterodimers, and with 
CD3-gamma, -delta and -epsilon, forms the T-cell receptor-CD3 complex. 
0.86 
RET ret proto-oncogene 0.86 
VEGFA vascular endothelial growth factor A 0.86 
PTPN1 protein tyrosine phosphatase, non-receptor type 1 0.86 
IL3RA The protein encoded by this gene is an interleukin 3 specific subunit of a 
heterodimeric cytokine receptor.  
0.84 
HDAC1 histone deacetylase 1,Together with metastasis-associated protein-2, it 
deacetylates p53 and modulates its effect on cell growth and apoptosis. 
0.82 
CCND1 The protein encoded by this gene belongs to the highly conserved cyclin 
family, whose members are characterized by a dramatic periodicity in 
protein abundance throughout the cell cycle.This protein has been shown to 
interact with tumor suppressor protein Rb and the expression of this gene is 
regulated positively by Rb. Mutations, amplification and overexpression of 
this gene, which alters cell cycle progression, are observed frequently in a 
variety of tumors and may contribute to tumorigenesis 
0.82 
FASN fatty acid synthase 0.82 
CD4 The protein functions to initiate or augment the early phase of T-cell 
activation, and may function as an important mediator of indirect neuronal 







Connecting GWAS reported genes with drug targets through the drug indication 
information from Drugbank. 
GWAS reported genes: We downloaded the GWAS catalog from 
http://www.genome.gov/admin/gwascatalog.txt in Jan 2012 and manually filtered out 
non-disease traits and combined studies for each disease. ‘Reported genes’ were 
extracted to provide the list of GWAS genes for each disease. 
Drug targets: We downloaded complete Drugbank data from 
http://www.drugbank.ca/downloads in January 2012. For each of the diseases in our 
GWAS gene list, we find corresponding drugs for that disease by searching the 
“indication” information for all drugs in Drugbank. Then for each of these drugs, we 
extract all of the corresponding target genes. 
Verified drug targets: We pick drug targets with the entry “Pharmacological action” 
labeled as “Yes” in the Drugbank. 
GWAS reported genes and drug targets were mapped to NCBI gene IDs to provide 
unique identifiers for comparison. The full set contains 1914 GWAS reported genes 
and 821 drug targets for 88 diseases. It contains a total of 4013 GWAS reported genes 
and 1463 drug target genes if we drop the restriction for the 88 diseases. The verified 
drug target set has 353 genes for 81 diseases. For each disease, we compare the list of 




Calculating expected overlap between GWAS reported genes and drug targets using a 
complete random model 
We estimate there are 20,000 human genes. For a specific disease, there are ‘m’ 
GWAS reported genes, and there are ‘n’ drug targets for this disease. Thus the 
expected random overlap between the two gene lists for that disease is n*m/20000. 
We calculated the expected overlap for each disease and then added them up to get 
the expected total number of overlap between drug targets and GWAS reported genes 
for the same disease. 
 
SNP impact analysis for GWAS genes and drug target genes 
1000 genome VCF data are downloaded from http://www.1000genomes.org/data 
The 2010 November data set is used. We extracted all non-synonymous variants from 
1000 genome data based on the Refseq annotation downloaded from UCSC genome 
browser on Jan 2012, and calculated the allele frequency for each of the non-
reference variants by dividing the number of alleles (count 1 for heterozygous and 2 
for homozygous)  by the number of total possible (2 times the number of people). 
 
We found non-synonymous SNPs in the coding regions of 3550 out of the 4013 
GWAS reported genes and 1249 out of the 1463 drug targets. We used our SNPs3D 
profile method  (Yue, Melamud et al. 2006) and PolyPhen2 (Adzhubei, Schmidt et al. 
2010) to predict the impact of these non-synonymous SNPs on protein function.  We 




targets and 2764 out of 3550 GWAS reported genes. We also obtained PolyPhen2 
predictions for 1227 out of 1249 drug target genes and 3484 out of 3550 GWAS 
reported genes.  
 
The density of non-synonymous SNPs in each gene is calculated by dividing the 
number of non-synonymous SNPs for that gene by the length of that gene’s protein 
sequence provided by the UCSC genome browser http://genome.ucsc.edu/. One 
splicing form is randomly chosen for each NCBI gene ID.  
 
The fraction of common negative impact SNPs are calculated as follows: For the 
SNPs3D profile method, the fraction is calculated by dividing the total number of 
common negative impact SNPs (allele frequency > 5% and SNPs3D score < 0 ) in a 
group of genes by the total number of common SNPs having a prediction score from 
SNPs3D in that group of genes. For PolyPhen2, the fraction is calculated by dividing 
the total number of common negative impact SNPs (allele frequency > 5% and 
Polyphen2 prediction “possibly damaging” or “probably damaging”) in a group by 
the total number of common SNPs having Polyphen2 predictions in that group. 
 
Transcript length analysis 
The longest transcript for each drug target and GWAS reported genes was picked 






Evolutionary analysis for GWAS reported genes and Drug target genes 
Ratios of non-synonymous to synonymous substitution rates, dN/dS,  for human 
proteins were downloaded from http://www.h-invitational.jp/evola/download.html in 
March 2012. The h-inv (Imanishi and Nakaoka 2009) IDs were converted to NCBI 
Gene IDs using a conversion map downloaded from http://biodb.jp/download.cgi. 
dN/dS from Human-Mouse orthologs and Human-Chimpanzee orthologs were 
selected. Human-Mouse dN/dS are considered to reflect selection over a relatively 
long time period, and Human-Chimpanzee dN/dS to reflect more recent history.  
 
Human gene network analysis for GWAS reported genes and drug target genes 
The Functional Interaction protein network  (Wu, Feng et al. 2010)  was downloaded 
from http://genomebiology.com/content/supplementary/gb-2010-11-5-r53-s3.zip. 
This un-weighted map consists of 209,988 functional interactions involving 10956 
proteins, and covers roughly half of the human coding genome. Gene symbols in this 
data set were converted to NCBI gene IDs. Finally 1125 out of 1914 GWAS reported 
genes and 611 out of 821 drug target genes for the 88 diseases and 932 drug targets of 
all 1463 drug targets were mapped into the network. 
 
The Floyd-Warshall algorithm (Floyd 1962) was used to calculate the shortest path 
between all gene pairs in the network. The resulting set of inter-node distances serves 




distances between GWAS genes for that disease, between drug targets genes, and 
between GWAS genes and drug target genes. For each disease, we also calculated the 
shortest path from every gene in the network to the nearest GWAS gene for that 
disease and to the nearest drug target for the disease. 
 
Machine learning for drug targets 
We use a random forest implemented in WEKA (Witten, Frank et al. 1999) to train 
on N+3 features to predict known drug targets for a disease from all drug targets. The 
training set is unbalanced because the number of drug targets for each disease is very 
small (median 28) compared to all possible drug targets, 932. We use the MetaCost 
procedure (Domingos 1999) to deal with the unbalanced training set, which gives 
more penalty to false negative errors than to false positive errors. We set the cost 
factor to be the ratio between the number of “correct” and “incorrect” drug targets. 
We set the parameter K, the number of separating features as the square root of the 
number of all features and set the parameter I, the number of decision trees in the 
random forest, as 50. 10 fold cross validation was used to measure the performance 
for the random forest method for each disease. 
 
3.4: Discussion 
In this chapter, we began by evaluating the capability of GWA studies to identify 
existing drug targets. From an analysis using Drugbank and the GWAS catalog, we 





Studies (Hindorff, Sethupathy et al. 2009) have shown that GWAS methods typically 
find high frequency SNPs with modest phenotype effects. On the other hand drug 
targets have big effect sizes with respect to disease phenotypes. We expect fewer high 
frequency deleterious SNPs in these genes and do observe this trend for non-
synonymous SNPs through analysis of population genomics data from the 1000 
genome project.  
 
Although we only look at the impact and distribution pattern of non-synonymous 
SNPs in these two set of genes, it’s likely that SNPs exerting their influence through 
other mechanisms (for example, altering the regulation of the expression of genes, 
changing the splicing pattern, changing the stability of messenger RNA) also follow 
the same pattern because the selection pressure is the same for all kinds of impact 
mechanisms. Through analysis of dN/dS for these two set of genes, we again found 
the selection pressure acting on drug targets is stronger than for GWAS reported 
genes. 
 
If drug targets genes are under strong negative selection so that they harbor fewer 
common SNPs with high negative effect, why do GWA studies not detect SNPs in 
these genes that have mild negative effects? To answer this question, it’s important to 
understand the spectrum of effect size generated by SNPs. For non-synonymous 
mutations, an analysis of the impact of mutations on the activity for seven different 




mutations are highly deleterious,  leading to at least a 10 fold decrease of assayed 
activity. So mild-effect non-synonymous SNPs may be rare because of an intrinsic 
property of protein mutations.  
 
The results are disappointing if our aim is discovering new drug targets directly from 
GWAS. However the close relationship between drug targets and GWAS reported 
genes makes the GWAS genes valuable reference points for finding new drug targets. 
Based on network features of human protein networks for GWAS reported genes and 
known drug targets, we developed a machine learning method to predict potential 
drug targets suitable for a specific disease from all existing drug targets in Drugbank. 
One of our initial proposals for new drug targets has now been confirmed.  
 
The present GWAS relies on common SNPs. With the development of new 
sequencing technology, high quality exome sequencing will to replace the role of 
DNA chips in GWAS studies (Kiezun, Garimella et al. 2012), and we already begin 
to  gain more insight into the role  of rare variants. For example, a recent exome deep 
re-sequencing project (Tennessen, Bigham et al. 2012) found there are a large number 
of rare SNVs in the human exome, most of which were previously unknown. A deep 
re-sequencing project for drug target genes has also found an abundance of rare 
functional variants (Nelson, Wegmann et al. 2012). These rare variants in drug target 
genes may play a role in risk of complex disease. All these data provide both 
opportunity and challenge for computational biology. Because of difference in 




statistical procedures need to be designed to detect association between rare SNVs 
and human diseases (Do, Kathiresan et al. 2012). For example, pooled association 
tests (Price, Kryukov et al. 2010) which combine rare variants in the same gene 
together provide a promising approach to address the problem. Another more straight-
forward way to establish the relationship between genes and diseases is to simply find 
genes that are mutated with high frequency in the diseases, a  practice adopted in 
many cancer studies (Kumar, White et al. 2011; Wang, Kan et al. 2011; Wei, Walia et 
al. 2011). For diseases like hypertension, many candidate genes have been discovered 
using non-genomic methods (Johnson, Newton-Cheh et al. 2011). Rare variants in 
these candidate genes in patients will be of great interest and may reveal key 
mechanisms in the development of the corresponding diseases as well as provide 














Chapter 4: Improved missense variant modeling accuracy using 
an Alignment Quality Estimator 
4.1: Introduction 
Missense single nucleotide variants in the human population are one of the principal 
causes of Mendelian disease (Stenson, Ball et al. 2009), and a major contributor to 
predisposition for cancer (King, Marks et al. 2003) as well as somatic driver 
mutations in these diseases (Shi and Moult 2011). They also play a significant role in 
common complex trait diseases (Gorlatova, Chao et al. 2011). More than three dozen 
computational methods have been developed to estimate the in vivo functional impact 
of these substitutions.  
 
Most of these methods rely on the phylogenetic pattern of residue use at the 
substitution position, utilizing the tendency of uncommon residues to have deleterious 
effect. 
 
For example, SIFT (Ng and Henikoff 2003) and the SNPs3D profile module (Yue, 
Melamud et al. 2006) predict the effect of a missense substitution based on the 
conservation of that amino-acid in close related species and the dissimilarity between 
the original amino acid and  the substituted one. The PolyPhen2 (Adzhubei, Schmidt 
et al. 2010) method employs a Bayesian model trained on a hybrid set of features 




based methods in principle capture all influences on fitness, they have the 
disadvantage of providing no direct insight into the underlying molecular mechanism. 
In particular, they are unable to distinguish between effects on protein function, such 
as altered enzymatic activity, allosteric regulation, or interaction with binding 
partners, and effects on protein folding and stability. In earlier work, we showed that 
about 75% of monogenic disease causing mutations act through these latter 
mechanisms. The SNPs3D structural module (Yue, Melamud et al. 2006) is a purely 
structure based prediction method aimed at identifying effects on protein 
thermodynamic stability. It uses an atomic level model of the protein to calculate 15 
physical and chemical features from the interactions of the original and substituted 
amino acids. A support vector machine (SVM), trained on mutations causative of 
monogenic disease and a control of set of interspecies variants, is then used to predict 
whether or not stability is significantly affected (typically a change of 2 Kcal/mol or 
greater).  
 
A limitation of the SNPs3D and other structural approaches is the need for a 
adequately accurate three-dimensional structure. At present, experimental structures 
cover only about 8% of known missense variants. Comparative modeling (Eswar, 
John et al. 2003) based on a template of a related structure provides a means of 
extending this coverage, but the more remote the template from the structure of 
interest, the less accurate the model.  Previous benchmarking of the SNPs3D method 
showed that down to 40% sequence identity between the template and the target 




models doubles the coverage of missense variants to 16%. If it were possible to 
extend coverage down to models based on 25% sequence identity, coverage would 
increase to 38%. Thus, we seek strategies for better coverage. 
 
There are two possible ways to increase coverage further than 40%. First, build more 
accurate models. A great deal of effort is already being placed into improving 
modeling methods, and although progress is being made, this is a tough problem 
(Kryshtafovych, Fidelis et al. 2011). Here we take the second approach, which is to 
identify those models built with existing methods that are already sufficiently reliable 
for the specific application of estimating the effect of a substitution on stability.  
 
The primary cause of the deterioration of model quality as template sequence identity 
falls is errors in alignment of the target and template sequences (Kryshtafovych, 
Fidelis et al. 2011). Misalignment by one residue position in the sequence causes a 
backbone error of 3.8Å, large enough for the values of the 15 features used in the 
SVM to be very seriously distorted. We have therefore developed a method that 
estimates the reliability of the alignment at the position of the amino acid substitution.  
The method employs the Smith-Waterman dynamic programming procedure to find 
the alignment between the target and template sequences with the maximum score 
(Smith and Waterman 1981; Waterman 1983). When the sequence identity between 
the target and template is low, it’s possible to generate several alternative alignments 
with marginal score differences. When this happens, it’s hard to tell which of these 




that we are picking a wrong alignment. In order to pick high confidence alignments, 
we developed an algorithm called Force-Bypass. The method perturbs the initial best 
alignment at the amino-acid position of interest to generate a new alignment differing 
at that position. The alignment score difference between the new alignment and the 
original one (score drop) is converted to the probability that the original alignment is 
correct at that position, using a calibration from a structurally determined set of 
alignments.  
 
We applied this algorithm to pick variants at high confidence alignment positions in 
low sequence identity models for variants in the SNPs3D training data. Retraining 
and benchmarking delivered significantly higher prediction accuracy on these 
compared to the low confidence ones. We then applied the method to pick high 
confidence low sequence identity models for missense SNVs from 1000 genomes 
project (Durbin, Altshuler et al. 2010), and by doing this, increased the number of 
model-able missense SNVs from 16% to 23%. The Force-bypass method developed 
in this paper can also be used in various situations of evolutionary analysis, in which 
the sequence identity is very low but the requirement for the accuracy at specific 
positions is stringent.    
 
4.2: Results 
Score Drop is a good criterion for Alignment quality 




Smith-Waterman (Smith and Waterman 1981; Waterman 1983) protein sequence 
alignment algorithm. The goal of this algorithm is to maximize the total alignment 
score, which is the sum of the residue pair scores over all positions. 
Residue pair scores may be calculated in a number of ways. We use a simple 
substitution matrix, and profile-profile matching. The substitution matrix reflects how 
“similar” a pair of aligned amino acids is. There are many different versions of 
substitution score matrices. Here we use the popular BLOSUM62 matrix (Henikoff 
and Henikoff 1992). In this matrix the substitution score between Lysine and 
Arginine is 2, reflecting the fact that they are highly similar amino acids, while the 
substitution score between Tryptophan and Arginine is -3, reflecting the fact that they 
are very different and pairing between them should be avoided in the alignment. 
Given pairwise scores for all possible matches of each residue in one sequence with 
each residue in the other, the Smith-Waterman algorithm employs dynamic 
programming to calculate the alignment with the highest score. That alignment is a 
best estimate of the historical equivalence of positions in the sequences. When the 
identity between the two sequences is low, several alignments may have similar 
scores. The ranking of these alignments depends heavily on the underlying pairwise 
scoring procedure, thus the alignment with the highest score is not necessarily the 
correct one. The similarity of scores for alternative alignments with respect to a 
particular residue is thus related to the probability that alignment is correct.  
 
To determine how robust the alignment at a particular position is we perturb the 




one with the highest score of all alignments with an alternative   pairing at the 
position we are interested in. Then we compare the alignment score of the alternative 
alignment with the highest score one (details in Methods). The difference between the 
scores of the two alignments is used as a measure of the reliability of the alignment at 
that position. To use this procedure to assign accuracy of alignments, we must have a 
gold standard alignment set to train our algorithm. Balibase (Thompson, Koehl et al. 
2005) is a set of manually curated multiple alignments of low identity protein 
sequences based on protein structural superimposition. The database is widely used 
for benchmarking sequence alignment algorithms (Karplus and Hu 2001). We convert 
the multiple sequence alignments in Balibase into pair-wise alignments. We then 
aligned each pair of sequences in Balibase with the standard Smith-Waterman 
algorithm. After that, we compared the pair-wise alignments extracted from Balibase 
with the alignments generated by the Smith-Waterman algorithm. We sorted the 
positions in the Smith-Waterman alignments into two categories: Correct ones, where 
Smith-Waterman is consistent with its Balibase counterpart; and incorrect ones, 
where Smith-Waterman is inconsistent with its Balibase counterpart. We then used 
our perturbation procedure to bypass each position in turn and calculate the score 
drop. 
 
Figure 4.1A shows the comparison of the score drop for these two categories of 
positions using the BLOSUM62 matrix. Correct alignments have a very distinct score 




Comparison between profile-profile alignment and substitution matrix based alignment 
Matching residue pairs on the basis of a profile-profile comparison produces more 
accurate alignments than those obtained using a single substitution matrix (von 
Ohsen, Sommer et al. 2003; Ohlson, Wallner et al. 2004), and has been especially 
popular in the field of structural modeling.  Profile-profile alignment is often 
performed with the Smith-Waterman algorithm or equivalent dynamic programming 
procedures (Rychlewski, Jaroszewski et al. 2000; Yona and Levitt 2002; von Ohsen, 
Sommer et al. 2003). The profile reflects the possibility of observing each type of 
amino-acid at each position in the sequence, and is usually generated by PSI-BLAST 
(Altschul, Madden et al. 1997). Then a score function is designed to provide a score 
between any pair of profiles aligned at a position. We implemented the weighted-sum 
(von Ohsen, Sommer et al. 2003) score function and performed the same procedure 
on the Balibase set as with the BLOSUM62 substitution matrix. We found that the 
profile-profile methods are more likely to get a correct alignment (Figure 4.1B). I.e., 
the proportion of consistent positions is higher (86%) in the profile-profile alignments 
than in the substitution matrix based alignments (76%). But the coverage is lower 
than that using the substitution matrix (Table 4.1). I.e., the number of aligned 






Table 4.1 Comparison of coverage and accuracy between BLOSUM62 and profile-
profile based alignments 




% consistent with Balibase 
 











Probability of a correct alignment as a function of score drop 
We bin the positions according to the score difference, and in each bin, we calculate 
the fraction of consistent positions as an empirical confidence measure (Figure 4.2A, 
4.3A). Using logistic regression, we can fit a confidence value function to each level 
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Figure 4.1 Distribution of score drops for positions consistent and inconsistent with 
Balibase alignments. A) Result generated using the Smith-Waterman algorithm with 
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Figure 4.2 A) Fraction of positions consistent with Balibase for each score drop value 
for BLOSUM62 alignment. B) Logistic regression for the probability of a correct 
alignment based on score drop values.  
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Figure 4.3 A) Fraction of positions consistent with Balibase for each score drop value 
for profile-profile scoring. B) Logistic regression for the probability of a correct 
alignment based on score drop values. 





SNPs3D performs better at high confidence alignment positions than at the low 
confidence ones 
As mentioned in the Introduction, our goal is to improve the quality of missense SNV 
impact prediction by filtering out low confidence alignments. We trained our SNPs3D 
structure predictor separately on high confidence alignment positions and on low 
confidence alignment positions, using low sequence identity models. The details of 
the SVM training is described in the previous paper (Yue, Melamud et al. 2006). The 
original predictor is trained on models built from PDB templates with at least 40% 
sequence identity. Where possible, we replaced each 40%+ sequence identity PDB 
template with a related structure with a sequence identity to the target protein 
between 25-40%, and rebuilt the models (see Methods). We then used the Force-
Bypass algorithm to generate alternative alignments and calculated score differences 
for each variant position in these low sequence identity models. We used 10 as a 
score difference cutoff for both BLOSUM62 and profile-profile alignments, 
corresponding to a confidence value (the fraction of alignments that are correct) of 
0.77 and 0.79 respectively. For each alignment method, we divided the models into 
two categories: high confidence ones (score drop >= 10) and low confidence ones 
(score drop < 10). The accuracy of predictions is higher for the high confidence 
models (Table 4.2), although the accuracy of these high confidence models is not as 
high as for 40%+ identity models (Table 4.2). Note that high false negative rates are 




affect in vivo protein function in multiple ways. We previously estimated (Yue, Li et 
al. 2005) that about 75% affect thermodynamic stability, and these are the true 
positives in our training set. On that basis, 25% false negatives is low as should be 
expected. Nevertheless, it is notable that the low quality models return larger false 
positives rates than the high quality ones, while the false positive rates are 
comparable.  
 
Table 4.2 Comparison of SNPs3D performance for different model sets 
 
False Positive False Negative 
   
40%-100% identity models 
 
18% 26% 
25-40% BLOSUM62  
(high confidence) 
 
























Examples of low sequence identity, high quality models 
NAGLU F410S 
NAGLU, alpha N-acetylglucosaminidase, is an enzyme that degrades heparan sulfate 
by hydrolysis of terminal N-acetyl-D-glucosamine residues in N-acetyl-alpha-D-
glucosaminides. Defects of enzyme are the cause of mucopolysaccharidosis type IIIB 
(MPS-IIIB), also known as Sanfilippo syndrome B. This disease is characterized by 
the lysosomal accumulation and urinary excretion of heparan sulfate (provided by 
RefSeq, Jul 2008). The mutation F410S is one of the disease mutations according to 
HGMD (Stenson, Ball et al. 2003).  There is currently no template in the PDB 
database that has 40% percent identity covering this position. The best model we can 
build uses PDB code 2VCC as a template. This protein is a glycocide hydrolase from 
Clostridium Perfringensi. The alternative alignment has a local score drop of 34.5, far 
in excess of our threshold of 10, and with an estimated probability of correct 
alignment of 0.97 (Figure 4.4). The SNPs3D predictor assigns this mutation as a 
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Figure 4.4  (A) Comparison of original and force-bypass alignments between 
NAGLU and the 2VCC_A template around the position of the F410S mutation. 
The alternative alignment doesn’t allow F410 in NAGLU to match with F541 in 




threshold 10, suggesting the original alignment is highly accurate.   (B) Structural 
model for the NAGLU build from 2VCC. From the model we can see the substitution 
of F410 to a Serine (S) leads to the loss of hydrophobic interaction between F410 to 
TRP353 and PHE384, resulting in loss of thermodynamic stability. 
 
ITGB4 C34Y  
ITGB4 is the β4 subunit of integrin. Integrin mediates cell-matrix or cell-cell 
adhesion, and transduced signals that regulate gene expression and cell growth. This 
gene encodes the integrin β4 subunit, a receptor for the laminins. This subunit tends 
to associate with the α6 subunit and is likely to play a pivotal role in the biology of 
invasive carcinoma. Mutations in this gene are associated with epidermolysis bullosa 
and with pyloric atresia. (provided by RefSeq, Jul 2008). The best model we can 
build from a PDB structural template that covers this disease causing mutation C34Y 
(Stenson, Ball et al. 2003)  has sequence identity 35.9% with the target. That is 
3IJE_B, a crystal structure of the β3 subunit of integrin. The score drop for the 
alternative alignment is 28, again well above the threshold 10, and corresponding to 
probability of alignment correctness of 0.95 (Figure 4.5). The SNPs3D method 
predicts this mutation to be destabilizing through breakage of a disulfide bridge and 
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Figure 4.5 (A) Alignment comparison between original and alternative alignments of 
1TGB4 and 3IJE_B. The alternative leads to a major re-organization of local 
alignment and a score drop of 28, suggesting the original alignment is accurate. (B) 
Structural model of 1TGB4 based on the 3IJE_B template. From the model it is clear 




and C14 and the big Tyrosine does not fit in the small space. Both of these effects are 
expected to contribute to destabilization of the protein. 
 
Increasing the number of model-able variants by picking high confidence alignments in 
low sequence identity models 
The 1000 genomes project provides us a deep catalog of human variations (Durbin, 
Altshuler et al. 2010). This rich information gives us an unprecedented opportunity to 
study the distribution and impact of human genomic variation at the population level. 
There are more than 170000 missense SNVs. Only ~16% of these (29160) have a 
structure template with more than 40% sequence identity.  By relaxing the sequence 
identity threshold to 25%, we can get many more models (total 66995), but a lot are 
of low quality. Using the procedure developed here, we obtained acceptable models 
for an additional 11030 SNVs, significantly increasing the structural coverage of 
SNVs from 16% to 23%.  
 
4.3: Methods 
Extracting pair-wise alignments from Balibase 
Balibase (Thompson, Koehl et al. 2005) multiple sequence alignments were 
downloaded from http://bips.u-strasbg.fr/fr/Products/Databases/BAliBASE/; on 2009. 
The reference1 dataset was used, which contains multiple sequence alignments of 




multiple sequence alignment is within a specific range. All the sequences within an 
alignment are of similar length, with no large insertions or extensions. All pair-wise 











  pair-wise alignments.  
 
Comparing Smith-Waterman alignments with extracted pair-wise alignments 
Each pair of extracted Balibase sequences was aligned using the Smith-Waterman 
algorithm using our program, in two ways. 1) With the BLOSUM62 substitution 
matrix, a gap open penalty of 10 and a gap extension penalty 0.5. 2) With the 
weighted sum score function (von Ohsen, Sommer et al. 2003) score between a pair 
of profile positions. The formula for calculating the score is as follows: 
20 20
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in which P and Q are two 20 dimension vectors generated using PSI-blast against the 
NR database (Altschul, Madden et al. 1997).  Pi is the probability of the amino-acid i 
at a specific position in the first sequence and Qj is the probability of the amino-acid j 
at a specific position in the second sequence, w(i,j) is the substitution score for amino-
acid i  and j from BLOSUM62. 
 
Then the Smith-Waterman alignment was compared with the corresponding Balibase 




the second sequence to the first sequence as in the Balibase alignment, then the 
position is considered to be a consistent position. Otherwise, that position is 
considered as an inconsistent position. 
 
Force-Bypass algorithm 
Before introducing the Force-Bypass algorithm, we briefly review the Smith-
Waterman algorithm. More details are in (Smith and Waterman 1981). The algorithm 
converts the problem of finding the highest score alignment between two sequences 
into a problem of finding the highest score path across a grid (Figure 4.6A), with 
horizontal and vertical steps denoting insertions and deletions and diagonal steps 
denoting matching of a pair of residues. The Smith-Waterman algorithm uses a 
dynamic programming procedure to find the path with the highest score across the 
whole grid, by finding the highest score path to every point in the grid. By a small 
trick of iteration, this problem is reduced to finding the smallest number among three 
numbers. 
 
Let the highest score to point (i, j) in the grid be H(i, j), we only need the highest 
score to its 3 adjacent points (i-1,j-1), (i-1,j) and (i,j-1) to calculate H(i, j) because 
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During the iteration, the highest score path to every point in the grid is stored. After 
we fill out the grid or we get to the border of the grid, we trace back each step stored 








Figure 4.6 Illustration of Smith-Waterman alignment method (A) and force-bypass 
algorithm (B). In (A) the algorithm has three choices at the 5th position in the first 
sequence, it can align the Proline with Lysine in the second sequence, or introduce a 
gap in the first sequence or introduce a gap in the second sequence. The best choice is 
aligning Proline with Lysine in this case. In (B), the Proline-Lysine alignment option 
is excluded, since it’s in the optimal alignment, the algorithm has to choose the path 
with highest score that doesn’t align K and P in these two sequences. 
 
We implemented the Force-Bypass algorithm within this framework, and assessed the 
accuracy of each position in the initial Smith-Waterman algorithm. The procedure 
basically uses the same iteration strategy as we described above. However, when the 
iteration arrives at the position we are interested in, it excludes the selection made by 
the Smith-Waterman algorithm, as a result, a next highest scoring path across the grid 




probability that the original alignment is correct. Since the new alignment may be of a 
different length, and the total alignment score depends on the length of the alignment, 
and this may change upon application of force-bypass.  To control for length 
differences, we only compare the scores for a fixed length 10 amino-acid fragment 
surrounding the position we are interested in.  
 
Annotating missense mutations in the 1000 genome data 
1000 genomes project phase I data was downloaded from 
http://www.1000genomes.org/data, in May 2011. The VCF file from the website 
contains the position of the variations and individual genotype for more than 1000 
people of various ethnic backgrounds. The REFSEQ human gene genomic position 
information was downloaded from the UCSC genome browser site  
http://genome.ucsc.edu/  in Jan 2012. We filter out the Refseq transcripts if: (1) The 
coding region is not a multiple of 3; (2) The coding region doesn’t start with a start 
codon; (3) The coding region doesn’t end with a stop codon. We use those SNVs 
from the VCF files only when the “filter” tag equals “PASS”. We end up with 177191 
missense SNVs. 
 
Structural modeling of missense variants 
Details of missense variant structural modeling can be found in our previous papers 
(Yue, Li et al. 2005; Yue, Melamud et al. 2006; Yue and Moult 2006). Here we give a 




choose the PDB crystal structure template with the highest sequence identity to the 
target protein that has a resolution better than 3Å. We copy the main chain from the 
template and build the side chain conformations using SCWRL (Wang, Canutescu et 
al. 2008; Krivov, Shapovalov et al. 2009). Given a protein structure that includes the 
residue substitution position, we calculate 11 protein stability features. There are four 
classes of electrostatic interaction: reduction of charge-charge, charge-polar or polar-
polar energy, or introduction of electrostatic repulsion; three solvation effects: 
burying of charge or polar groups, and reduction in non-polar area buried on folding; 
and two terms representing steric strain: backbone strain and over-packing. The other 
two features considered are cavity formation (affecting van der Waals energy), and 
loss of a disulfide bridge. Surface accessibility of the mutated residue relative to the 
unfolded state is also included, as well as three parameters related to the Cα 
temperature factor of the altered residues, so that there are 15 parameters in total. We 
use SVMlight software http://svmlight.joachims.org/  to determine the partitioning 
surface between the disease and non-disease SNVs in the 15-dimensional feature 
space. Continuous variables were normalized in the form of a Z score (Z = (value-
mean)/standard-deviation). A radial basis kernel with a g value of 0.2 was used with a 
cost factor equal to the ratio between number of negative cases and the number of 
positive cases. 
 
Measuring the performance of variant impact modeling for different sets of models 




which are in our previous papers (Yue, Li et al. 2005; Yue and Moult 2006). The 
deleterious variants are a set of single amino acid substitutions known to cause 
monogenic disease. Genes associated with monogenic disease were identified by 
checking the Human Gene Mutation  Database10 (HGMD) (as of 9 February 2002) 
(Krawczak, Ball et al. 2000). HGMD contains a collection of mutations related to 
genetic diseases. Most of the mutations cause monogenic disease, although a few may 
be associated with disease as a result of linkage disequilibrium rather than directly 
causative, or contribute to a complex trait disease. Later versions of HGMD include 
more of the latter class, and so the earlier version was preferred and used here. For the 
neutral variants set, we used missense base differences between human proteins and 
orthologs in mouse. The justification here is that almost all variants that are fixed 
between species are essentially neutral and non-deleterious.  
 
We use 30 rounds of bootstrapping to benchmark the performance of the SVM 
predictor trained on the 15 structural features described previously. For each round 
we sampled the training data with replacement, as a result 63% of the data points are 
sampled and treated as training data and the remaining 37% are treated as validation 
data. False positive and false negative rates are calculated from the validation data. 
We take the average of the 30 rounds as the final false positive rate and false negative 
rates.  
 
We perform the benchmarking procedures on the SVMs trained on five sets of data 




based on PDB templates of higher than 40% sequence identity to the protein of 
interest.  2) Protein models based on PDB templates of sequence identity between 
25% and 40%, and the score drop for each mutation position calculated by our force 
bypass algorithm with the BLOSUM62 matrix is larger or equal to 10. 3) Protein 
models based on PDB templates of sequence identity between 25% and 40%, and the 
score drop for each mutation position calculated by our force bypass algorithm with 
the BLOSUM62 matrix is smaller than 10. 4) Protein models based on PDB templates 
of sequence identity between 25% and 40% and the score drop for each mutation 
position calculated by our force bypass algorithm with profile-profile scores is larger 
or equal to 10. 5) Protein models based on PDB templates of sequence identity 
between 25% and 40% and the score drop for each mutation position calculated by 
our force bypass algorithm with profile-profile scores is smaller than 10. Using these 
criteria, we get 13154 variant models for set 1, 5712 models for set 2, 7036 models 
for set 3, 5012 models for set 4 and 3512 models for set 5. 
  
4.4: Discussion 
In this work, we developed a method to assess the accuracy of low sequence identity 
alignment at a single position and applied the method to SNV impact modeling. There 
are several pre-existing methods to access the accuracy of alignments. For example, 
(Holmes and Durbin 1998) address this problem by simulating the process of random 
mutation for pairs of initially identical sequences to generate pseudo orthologous 




supposed correct alignments. iRMSD (Armougom, Moretti et al. 2006) evaluates 
alignment accuracy using structure information based on the rationale that physical 
distance among correctly aligned amino acids should be similar in the two aligned 
proteins, and it requires solved protein structures. These methods do not provide the 
accuracy of a specific position for an alignment, crucial in applications such as SNV 
impact prediction.  
 
Although it is sometimes possible to spot a bad alignment around a position by visual 
inspection, our method provides a more rigorous and high through-put way to do that, 
making it suitable for high throughput applications. As data from exome and full 
genome sequencing accumulate, there is an increasing need for such methods. For 
example, a recent exome deep re-sequencing project (Tennessen, Bigham et al. 2012) 
found there are a large number of rare SNVs in the human exome, most of which 
were previously unknown. The more high quality structure models we can build, the 
more we can take advantage of these data. Our method can be applied to such datasets 
in a similar fashion as we demonstrated using the 1000 genomes data (Durbin, 
Altshuler et al. 2010). 
 
The method is not only applicable to SNV impact modeling, but also useful for 
evolutionary analysis, especially for those tasks requiring high accuracy alignment for 
low identity sequences at specific positions. For example, a recent study used 
comparative biology approaches to investigate the evolution of protein 




of these phosphorylation sites required alignment of sequences from widely diverged 
organisms. The accuracy of the alignments, especially for the phosphorylation sites, is 
crucial for their work. Our method could be applied to these data in order to increase 
accuracy. 
 
The force-bypass algorithm is implemented in a java program and free for use. We 

















Chapter 5:  Conclusions and perspectives 
In this dissertation, we demonstrated the value of computational methods in 
addressing a wide range of problems in protein structure, evolution, and networks. 
Here we give a brief summary of the conclusions for each project and discuss the 
future directions in each area. 
5.1: Population Genomics:  studying evolution in detail 
In the first part of my dissertation, we investigated several evolutionary biology 
problems from the perspective of population genomics, using data from the 1000 
genomes project (Durbin, Altshuler et al. 2010). First we investigated the relationship 
between the impact of non-synonymous SNVs and their population frequency. We 
found deleterious SNVs generally have low population frequencies, providing 
evidence of purifying selection at the population genomics level. Second, we 
investigated possible reasons for correlation between dN and dS using different 
categories of SNV densities. We found that the analogous population level measures 
of dN and dS, non-synonymous SNV density and synonymous SNV density, do 
correlate with each other and both are strongly correlated with intron SNV density. 
Using partial correlation analysis we showed that the correlation between the density 
of non-synonymous and synonymous SNVs arises both because of local mutation rate 
variation across the genome and shared selection pressure on these classes of SNV. 
We propose that the correlation between dN and dS also arises from the same two 




Third, we investigated the influence of two factors (mRNA expression level and 
number of protein-protein interactions) on the density of non-synonymous and 
synonymous SNVs and found that they both negatively correlate with the density of 
ns-SNVs. We also found that the correlation between predicted high impact ns-SNV 
density and mRNA expression level is higher than the correlation between neutral ns-
SNV density and mRNA expression, which gives population level support to the mis-
folding error model (Drummond, Raval et al. 2006). We also checked genes that 
deviate markedly from this trend and found most are immune-related., suggesting that 
the advantages of population diversity in these genes off-sets the fitness cost 
associated with increased mis-folding.  
 
As new generation sequencing becomes cheaper and faster, there will be an explosion 
in deep sequencing data for human genomes. Those data will make it possible to 
investigate human evolution problems at a new level of detail. In this project, we 
focused on the evolution in coding regions, but in the future, there is much work to do 
on non-coding regions. For example, the human regulatory network constructed as 
part of the ENCODE project  (Gerstein, Kundaje et al. 2012) provides us with a 
detailed map of human gene regulation.  Integrating this data with the upcoming 
human sequencing data in a similar manner as we did in this project will help us 
understand evolution of human regulatory elements, especially in recent human 
history. By combined analysis of the human regulatory map, human population 
genomes and other functional databases, such as the human protein functional 




Goldsmith et al. 2004) , we will understand the evolution of human regulatory 
networks at a new level. Combining the analysis of evolution for coding and 
noncoding regions will also let us study the interplay between the evolution of human 
regulatory networks and human coding sequences (Carroll 2005; Gemayel, Vinces et 
al. 2010), which will help in understanding genome evolution from a holistic 
perspective. 
 
5.2: Integration of GWAS with other knowledge and the future of GWAS 
with rare variants 
In the second part of my dissertation, I studied the ability of GWAS to discover 
mechanism genes through combined analysis of data from the GWAS catalog and 
Drugbank. We discovered that for 856 drug targets that have corresponding GWA 
studies, only 20 are identified. We investigated several possible reasons to explain 
this observation, and found two that contribute: (1) Drug target genes are strongly 
coupled with the disease phenotype, as a result, they have fewer common deleterious 
SNPs. (2) The probability of a gene being reported by GWAS is related to its 
transcript length and GWAS reported genes are generally longer than drug targets. 
Although we found GWA studies are not effective at discovering drug targets 
directly, we found that drug targets and GWAS reported genes are closely related in 
the biological network. Based on this observation, we designed a machine learning 






The GWAS catalog is a public resource to facilitate the exchange and publication of 
experimental results, and it is useful for people with interest in specific diseases. But 
this centralized data resource is not been explored to its full potential when only used  
as a collection of independent results for different diseases. In our study, we combine 
the GWAS catalog with Drugbank and a Human protein functional interaction 
network. This allows us to understand the common properties of all the GWAS 
results as a whole, both their strengths and weaknesses. There are many more 
interesting large scale datasets for us to explore in the future. To name a few: 
mammalian phenotype ontology (Smith, Goldsmith et al. 2004) and Large scale 
literature mining data generated from many different methods (Marcotte, Xenarios et 
al. 2001; Becker, Hosack et al. 2003; Korbel, Doerks et al. 2005; Jensen, Saric et al. 
2006). These possibilities also raise challenges in natural text processing, such as we 
have already faced when capturing  drug information for specific diseases, as well as 
clustering GWA studies of the same disease that have different names. If we want to 
integrate this information with the phenotype ontology and literature knowledge or 
other knowledge resources, the challenge is even bigger. To invent new algorithms or 
methodology for this kind of task is probably not a role computational biologists 
should play, but it requires us to keep up with new methods invented by our 
colleagues in the machine learning community (Cohen and Hunter 2004; Verspoor, 
Cohen et al. 2012). 
 




Stringer, Wray et al. 2011), SNPs reported in GWAS are usually common, mild effect 
SNPs. The introduction of next generation sequencing will gradually change this 
situation. The cancer genome atlas (Hampton 2006) project has established that a 
large diversity of missense somatic variants are involved in cancer. A large scale 
exome sequencing project for early onset myocardial infarction has found many rare 
variants in some candidate genes for cardiological diseases (Stitziel 2012), suggesting 
these will explain a substantial fraction of the heritability not accounted for by 
GWAS. As whole exome and whole genome sequencing for GWAS becomes 
affordable, we will be confronted with more and more rare variants. To study the 
relationship between rare variants with disease requires a completely different 
methodology from traditional GWA studies, and new statistical procedures are being 
developed (Price, Kryukov et al. 2010) that will help us understand the genetic basis 
of complex disease at a new level. 
 
5.3 Protein modeling and the future of personal medicine 
In the third part of my dissertation, I first studied the relationship between accuracy of 
pairwise protein sequence alignment and the alignment score drop using multiple 
alignments from Balibase as a benchmark. We used this measure to pick high 
accuracy alignments suitable for building high quality structural models of human 
missense SNV impact. We found that by adopting this strategy, we can increase the 
coverage of the missense SNVs from 16% to 23% without losing too much accuracy. 




et al. 2011), common complex disease (Stitziel 2012), and cancer (Wei, Walia et al. 
2011) (Yan, Xu et al. 2011) are all beginning to generate data containing many 
previously unobserved missense variants, and determining which of these contribute 
to the disease phenotype is an increasingly central problem. As a consequence, there 
are urgent challenges in this area for both experimental structural biologists and 
computational structural biologists. On the one hand, structural genomics people are 
working hard to solve more structures for every protein family (Dessailly, Nair et al. 
2009). On the other hand, computational biologists are developing new methods to 
build better models (Bourne 2009). If experimental structures and computational 
models can cover all human proteins, then we can explain many of the rare variants 
data in a biologically meaningful way, which will not only help us understand the 
mechanism of complex diseases but also help us develop therapeutics in an individual 
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